<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6105696</article-id><article-id pub-id-type="pmcid-ver">PMC6105696.1</article-id><article-id pub-id-type="pmcaid">6105696</article-id><article-id pub-id-type="pmcaiid">6105696</article-id><article-id pub-id-type="pmid">30166987</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.01891</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Therapies to Suppress &#946; Cell Autoimmunity in Type 1 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kroger</surname><given-names initials="CJ">Charles J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/498327"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clark</surname><given-names initials="M">Matthew</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/508162"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ke</surname><given-names initials="Q">Qi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/597284"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tisch</surname><given-names initials="RM">Roland M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="fn001">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/27612"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Microbiology and Immunology, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</institution>, <addr-line>Chapel Hill, NC</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Gustavo Javier Martinez, Rosalind Franklin University of Medicine and Science, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Abdel Rahim A. Hamad, Johns Hopkins University, United States; Maja Wallberg, University of Cambridge, United Kingdom; Rachel Friedman, National Jewish Health, United States</p></fn><corresp id="fn001">*Correspondence: Roland M. Tisch, <email>rmtisch@med.unc.edu</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">305241</issue-id><elocation-id>1891</elocation-id><history><date date-type="received"><day>14</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2018</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>30</day><month>08</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2018-09-02 01:06:26.443"><day>02</day><month>09</month><year>2018</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2018 Kroger, Clark, Ke and Tisch.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Kroger, Clark, Ke and Tisch</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-09-01891.pdf"/><abstract><p>Type 1 diabetes (T1D) is an autoimmune disease that is generally considered to be T cell-driven. Accordingly, most strategies of immunotherapy for T1D prevention and treatment in the clinic have targeted the T cell compartment. To date, however, immunotherapy has had only limited clinical success. Although certain immunotherapies have promoted a protective effect, efficacy is often short-term and acquired immunity may be impacted. This has led to the consideration of combining different approaches with the goal of achieving a synergistic therapeutic response. In this review, we will discuss the status of various T1D therapeutic strategies tested in the clinic, as well as possible combinatorial approaches to restore &#946; cell tolerance.</p></abstract><kwd-group><kwd>autoimmunity</kwd><kwd>diabetes</kwd><kwd>immunoregulation</kwd><kwd>immunotherapy</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn01">R01DK100256, R01DK1035486 and T32AI007273</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="240"/><page-count count="14"/><word-count count="13438"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Type 1 diabetes (T1D) is an autoimmune disease marked by the dysfunction and/or destruction of the insulin-producing &#946; cells found in the pancreatic islets of Langerhans (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>). T1D most often arises in children but also develops in adults. To compensate for impaired &#946; cell function, T1D individuals require daily insulin therapy. Despite insulin administration, however, establishing optimal glycemic control long-term is often problematic resulting in a number of complications, including retinopathy, nephropathy, vasculopathy, and neuropathy. This morbidity coupled with an increasing incidence of T1D world-wide, underscores an urgent need for effective immunotherapies for T1D prevention and treatment.</p><p>The goal of an immunotherapy is threefold: (1) selectively suppress ongoing autoimmunity, (2) reestablish self-tolerance long-term, and (3) preserve acquired immunity. This review will focus on the different strategies of immunotherapy being tested experimentally and in the clinic to suppress &#946; cell autoimmunity, and prevent clinical onset and/or treat T1D.</p></sec><sec id="S2"><title>Immunopathology of T1D</title><p>The loss of &#946; cell tolerance involves both genetic and ill-defined environmental factors (<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>). A strong genetic association with specific human leukocyte antigen haplotypes, coupled with several variants of genes expressed by &#946; cells, T cells, and other immune effectors underscore the complexity of the autoimmune response of T1D (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>). &#946; cell autoimmunity is typically viewed as a chronic inflammatory response characterized by the progressive infiltration of the pancreatic islets with various immune effectors (<xref rid="B24" ref-type="bibr">24</xref>). In the nonobese diabetic (NOD) mouse, a spontaneous model of T1D, islet infiltration is initiated at an early age by macrophages and dendritic cells (DC), CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and B cells. This insulitis initially exhibits benign properties with little effect on &#946; cell viability or function. However, at a late preclinical stage, an ill-defined qualitative change occurs within the islet infiltrate, which promotes efficient &#946; cell destruction leading to the onset of overt diabetes. In NOD mice and other rodent models of T1D, pathogenic &#946; cell-specific CD4<sup>+</sup> and CD8<sup>+</sup> effector T cells (Teff) are essential drivers of autoimmunity. Diabetogenic CD4<sup>+</sup> and CD8<sup>+</sup> T cells target several &#946; cell autoantigens and related peptide epitopes, including proinsulin/insulin, glutamic acid decarboxylase 65 (GAD65), chromogranin A (ChgA), zinc transporter 8 (ZnT8), glucose-6-phosphatase catalytic subunit-related protein (IGRP), and hybrid insulin peptides (HIPs) among others (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B34" ref-type="bibr">34</xref>). It is thought that early in the disease process only few &#946; cell autoantigens and epitopes are targeted by T cells. However, over time additional epitopes within a given autoantigen as well as new autoantigens are recognized. Furthermore, chronic inflammation negatively affects &#946; cells in part by generating neo-autoantigens, such as HIPs, <italic toggle="yes">via</italic> post-translational modification events (<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>). These neo-autoantigens further diversify the diabetogenic response. Together this epitope spread effectively amplifies the &#946; cell-specific T cell response (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>).</p><p>Analyses of human cadaveric T1D pancreases have also demonstrated islet infiltrates consisting of CD8<sup>+</sup> T cells and macrophages, and to a lesser extent CD4<sup>+</sup> T cells, and B cells (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B43" ref-type="bibr">43</xref>&#8211;<xref rid="B52" ref-type="bibr">52</xref>). However, T1D pancreases have been reported that lack T cell infiltrates suggesting that the immunopathology of human T1D is heterogeneous (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). The prevalence of T cell-independent subsets of T1D is unclear, and thought to be primarily associated with adult T1D onset. On the other hand, evidence indicates that the rapid and severe T1D that develops in children and adolescents is T cell-mediated (<xref rid="B44" ref-type="bibr">44</xref>). For instance, recent reports show that childhood onset is marked by a broader and more aggressive &#946; cell-specific T cell response compared to adult T1D (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B43" ref-type="bibr">43</xref>&#8211;<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B55" ref-type="bibr">55</xref>&#8211;<xref rid="B57" ref-type="bibr">57</xref>). Multiple &#946; cell autoantigens are recognized by human CD4<sup>+</sup> and CD8<sup>+</sup> T cells found in peripheral blood, as well as the islets of T1D subjects; many of which are also targeted in the NOD mouse diabetogenic response (e.g., insulin, GAD65, IGRP, and ZnT8) (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B57" ref-type="bibr">57</xref>).</p><p>Pathogenic &#946; cell-specific CD4<sup>+</sup> and CD8<sup>+</sup> Teff in NOD and human T1D typically exhibit a type 1 or T helper 1 (Th1) phenotype marked by IFN&#947; production (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). IL-17-producing CD4<sup>+</sup> Th17&#8201;cells have also been implicated in mediating &#946; cell destruction (<xref rid="B60" ref-type="bibr">60</xref>&#8211;<xref rid="B62" ref-type="bibr">62</xref>). Differentiation and expansion of pathogenic Teff are in part attributed to aberrant peripheral immunoregulation (<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B68" ref-type="bibr">68</xref>). An impaired pool of thymic-derived FoxP3-expressing immunoregulatory T cells (Foxp3<sup>+</sup>Treg) has been linked to T1D (<xref rid="B68" ref-type="bibr">68</xref>&#8211;<xref rid="B70" ref-type="bibr">70</xref>). In general, Foxp3<sup>+</sup>Treg play an essential role in maintaining peripheral self-tolerance through cytokine and contact-dependent mechanisms of suppression (<xref rid="B71" ref-type="bibr">71</xref>). Decreased survival of islet-resident Foxp3<sup>+</sup>Treg is thought to be a key factor in promoting the progression from benign to pathogenic insulitis in NOD mice (<xref rid="B69" ref-type="bibr">69</xref>). Failure to maintain islet Foxp3<sup>+</sup>Treg numbers in NOD mice is due to insufficient local levels of IL-2, a critical cytokine needed for Foxp3<sup>+</sup>Treg survival, fitness, and function (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B74" ref-type="bibr">74</xref>). FOXP3<sup>+</sup>Treg from T1D subjects have defective IL-2 receptor (R) signaling which limits fitness and function of FOXP3<sup>+</sup>Treg (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B75" ref-type="bibr">75</xref>). Additionally, production of the proinflammatory cytokine IL-21, which is critical for T1D development, can inhibit IL-2 expression by T cells which negatively impacts Foxp3<sup>+</sup>Treg viability and function (<xref rid="B76" ref-type="bibr">76</xref>). Human T1D is also marked by deficiencies in non-FoxP3-expressing adaptive (a) Treg. For example, the frequency of &#946; cell-specific IL-10-secreting Tr1 cells is reduced in T1D versus healthy subjects (<xref rid="B77" ref-type="bibr">77</xref>&#8211;<xref rid="B79" ref-type="bibr">79</xref>). In both NOD and human T1D, Teff exhibit a reduced sensitivity to Treg-mediated suppression, which further permits expansion of the diabetogenic Teff pool (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>).</p><p>Dysregulation among antigen-presenting cells (APC), such as DC, macrophages, and B cells, has also been reported to contribute to T1D (<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B85" ref-type="bibr">85</xref>). Although detection of autoantibodies is a key indicator of &#946; cell autoimmunity, B cells are thought to play a critical role in the development of T1D by functioning primarily as an APC (<xref rid="B86" ref-type="bibr">86</xref>&#8211;<xref rid="B88" ref-type="bibr">88</xref>). APC exhibiting proinflammatory properties also skew differentiation of na&#239;ve &#946; cell-specific T cells toward pathogenic Teff, as well as amplify islet inflammation and &#946; cell destruction. For instance cytokines, such as IFN&#947;, TNF&#945;, and IL-1&#946; secreted by islet APC are cytotoxic to &#946; cells <italic toggle="yes">in vitro</italic> (<xref rid="B89" ref-type="bibr">89</xref>). The culmination of the adaptive and innate effector immune response within the islets results in &#946; cell destruction/dysfunction and elevated blood glucose levels (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>The progression and treatment of &#946; cell autoimmunity. <italic toggle="yes">Top panel</italic>: In general, overt diabetes results from the gradual loss of functional insulin-producing &#946; cells due to the inflammatory environment driven by infiltrating self-reactive T cells and antigen-presenting cells (APC). Although &#946; cell-specific T cell clones are detected in both healthy and type 1 diabetes (T1D) susceptible individuals, a number of factors promote T1D development in the latter population. Decreased efficiency of negative selection in the thymus allows for the increased escape of &#946; cell-specific T cell clones into the periphery. In the periphery, &#946; cell-specific T cells are stimulated in the pancreatic lymph nodes (PLN) by APC derived from the islets, leading to effector T cells (Teff) differentiation due to suboptimal Foxp3<sup>+</sup>Treg suppression. These pathogenic Teff then infiltrate the islets and drive inflammation leading to reduced &#946; cell function and/or survival. <italic toggle="yes">Bottom panel</italic>: Several distinct therapeutic interventions have been tested for the prevention or treatment of T1D. The major approaches have included: administration of &#946; cell autoantigens, expansion of Foxp3<sup>+</sup>Treg, Ab therapies that alter T cell responses, therapeutic reagents that tolerize APC function, neutralization of proinflammatory molecules, or treatments that expand or enhance &#946; cell function and/or survival. Some of these approaches have had clinical, albeit limited, success. Future therapeutic interventions should look toward refinement in the specificity of these treatments, and the development of combinatorial therapies targeting multiple arms of the immune system, as T1D is a multi-pronged autoimmune disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-09-01891-g001.jpg"/></fig><p>Aberrant peripheral immunoregulation has been the focus of most T1D immunotherapies. Different strategies have attempted to selectively suppress the pathogenic proinflammatory events that affect &#946; cells, while reestablishing protective immunoregulation that persists long-term without altering acquired immunity (Figure <xref ref-type="fig" rid="F1">1</xref>). Achieving these goals in the clinic, however, has proven to be highly challenging.</p></sec><sec id="S3"><title>Immunotherapy of T1D</title><p>The progression of T1D affords three windows of therapeutic intervention to alter disease outcome (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). The first is during the prodromal stage of T1D, which may persist for a number of years. At-risk individuals with ongoing &#946; cell autoimmunity, identified by serum autoantibodies specific for various &#946; cell autoantigens, are candidates for prevention of clinical onset of T1D (<xref rid="B90" ref-type="bibr">90</xref>&#8211;<xref rid="B92" ref-type="bibr">92</xref>). The second window of intervention is at the time of clinical onset. The goal here is to suppress &#946; cell autoimmunity, rescue residual &#946; cell mass, and ideally reverse clinical diabetes. Early studies provided proof of principle that sufficient &#946; cell mass exists at the time of diagnosis to reverse diabetes (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Administration of the immunosuppressive drug cyclosporine A (CsA) induces remission in new onset children. However, CsA results in severe kidney toxicity, and once therapy is halted, patients develop recurrent diabetes (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). The third window of intervention is in long-standing T1D patients to protect residual &#946; cell function. Evidence indicates that after T1D onset low but sustained C-peptide levels are observed (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Therefore, maintenance of a small amount of functional &#946; mass may aid in the control of glycemia as well as limit morbidity.</p><p>Two general approaches of immunotherapy have been tested experimentally and in the clinic for the prevention and treatment of T1D. The first approach entails manipulating the autoimmune response independent of &#946; cell specificity. Typically, antibodies (Ab) targeting specific immune effectors or effector molecules have been employed for this approach. The second approach makes use of &#946; cell antigen-specific strategies. Here, &#946; cell autoantigens or corresponding peptides are administered under various conditions. In the following sections, we will discuss different strategies of immunotherapy that are included in these two general approaches, highlighting related strengths and weaknesses (Figure <xref ref-type="fig" rid="F1">1</xref>).</p></sec><sec id="S4"><title>Antigen-Independent Immunotherapies</title><p>Ab and cytokines have been administered to modulate or block the function of immune effector cells and/or molecules. The general approach is advantageous, since pathogenic effectors can be targeted <italic toggle="yes">en masse</italic>, often resulting in rapid and robust outcomes in experimental settings. However, the limited specificity of these therapeutics can lead to unwanted systemic effects impacting acquired immunity for instance. Nevertheless, a sizable body of work has demonstrated clinical efficacy for certain Ab therapies, whereas promising early results are being seen with cytokine- and cell-based strategies.</p><sec id="S4-1"><title>Antibody-Based Therapies</title><p>Arguably, the most effective strategy to clinically alter T1D progression has been to target diabetogenic Teff with anti-CD3 monoclonal Ab (mAb) (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). In new onset NOD mice anti-CD3 mAb therapy reverses diabetes in part by driving apoptosis of islet-infiltrating Teff. Engulfment of the apoptotic T cells induces TGF-&#946; secretion by APC that promotes differentiation of Foxp3<sup>+</sup>Treg. Once established this pool of induced (i) Foxp3<sup>+</sup>Treg mediate long-lasting &#946; cell tolerance (<xref rid="B99" ref-type="bibr">99</xref>&#8211;<xref rid="B101" ref-type="bibr">101</xref>). In addition, peripheral Teff exhibit reduced IFN&#947; production, and increased markers of exhaustion and anergy (<xref rid="B102" ref-type="bibr">102</xref>). Interestingly, anti-CD3 mAb therapy given at a preclinical stage fails to prevent diabetes onset in NOD mice (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B103" ref-type="bibr">103</xref>). This indicates that a given immunotherapy may be effective only at particular stages of T1D progression.</p><p>For clinical trials, humanized anti-CD3 mAb hOKT3&#947;1 (Ala-Ala) (teplizumab) or CCHAglyCD3 (otelixizumab) have been engineered to prevent binding to Fc receptor, and minimize proinflammatory cytokine release by APC (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B104" ref-type="bibr">104</xref>&#8211;<xref rid="B112" ref-type="bibr">112</xref>). Anti-CD3 mAb therapy administered to new onset T1D patients reduces the rate of loss of &#946; cell function in the majority of individuals (<xref rid="B113" ref-type="bibr">113</xref>). The mechanism of protection is ill-defined, although expansion of CD8<sup>+</sup> Treg and CD8<sup>+</sup> Teff exhibiting an exhausted phenotype has been reported (<xref rid="B109" ref-type="bibr">109</xref>). Despite this efficacy, diabetes reversal is not achieved, and protection of residual &#946; cell mass is short-term, lasting up to 4&#8201;years in some individuals (<xref rid="B113" ref-type="bibr">113</xref>). Furthermore, anti-CD3 mAb binding can activate T cells resulting in cytokine release and unwanted inflammation, albeit transient. Moreover, the transient depletion of T cells systemically by anti-CD3 mAb is linked to recurrent viral infections (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B104" ref-type="bibr">104</xref>). Nevertheless, these findings provide direct evidence that progression of &#946; cell autoimmunity can be modulated by targeting T cells. However, further refinement of the approach is required to enhance &#946; cell protection while minimizing effects on acquired immunity. This may in part be achieved by using anti-CD3 mAb in combination with other therapeutics (<xref rid="B114" ref-type="bibr">114</xref>&#8211;<xref rid="B116" ref-type="bibr">116</xref>). For instance, treatment of NOD mice with anti-CD3 mAb and the &#946; cell trophic growth factor prolactin, increases both diabetes reversal and &#946; cell proliferation relative to anti-CD3 mAb alone (<xref rid="B116" ref-type="bibr">116</xref>).</p><p>The aim of Ab-based combinatorial strategies is to establish a synergistic or additive effect to enhance both efficacy and safety. An increased tolerogenic response may permit reduced dosing and, therefore, minimize unwanted complications with a given therapeutic. One combinatorial strategy being tested in the clinic is the application of antithymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF). Low dose ATG induces apoptosis and transiently depletes T cells, whereas G-CSF promotes mobilization of aTreg and induction of tolerogenic DC. In preclinical studies, ATG alone induces ~30% remission in newly diabetic NOD mice, whereas the combination of ATG and G-CSF increases diabetes reversal &gt;twofold (<xref rid="B117" ref-type="bibr">117</xref>). Initial phase I clinical results for low dose ATG plus G-CSF therapy given to recent onset T1D patients indicate that &#946; cell function can be maintained up to 2&#8201;years in a group of responders (<xref rid="B118" ref-type="bibr">118</xref>). This protective effect correlates with quantitative and qualitative changes in the conventional T cell pool, coupled with an increase in the frequency of FOXP3<sup>+</sup>Treg (<xref rid="B118" ref-type="bibr">118</xref>).</p><p>Although most T1D immunotherapies have targeted T cells, success has also been demonstrated by altering the B cell response in various autoimmune diseases including T1D, both in mice and humans (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). As previously mentioned, serum autoantibodies indicate B cells also target &#946; cell antigens, including GAD65 and insulin, which serve as a biomarker for individuals with an increased risk for developing T1D (<xref rid="B90" ref-type="bibr">90</xref>&#8211;<xref rid="B92" ref-type="bibr">92</xref>). NOD mice lacking B cells are protected from insulitis and diabetes onset (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Several molecules, such as CD20, CD22, BAFF, and BCMA have been targeted to modulate the B cell pool (<xref rid="B121" ref-type="bibr">121</xref>&#8211;<xref rid="B125" ref-type="bibr">125</xref>). In different murine models of T1D, anti-CD20 mAb suppresses the progression of &#946; cell autoimmunity as well as reverses diabetes onset, by promoting Foxp3<sup>+</sup>Treg and regulatory B cell populations (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). In recent onset T1D patients, anti-CD20 mAb (Rituximab), which has also been used in the treatment of rheumatoid arthritis (RA), transiently depleted B cells and prolonged &#946; cell function (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>). However, this protective effect was only transient, diminishing after 1&#8201;year, suggesting brief deletion of B cells alone is not sufficient to restore &#946; cell tolerance.</p><p>The depleting effects of a given Ab make dosing problematic, as well as limit the frequency of treatments. On the other hand, nondepleting (ND) Ab provide a strategy to modulate the function of Teff and other immune cells without systemic cell depletion. Human IgG4 is intrinsically ND due to a decreased capacity to fix complement and bind to Fc receptor, and, therefore, is well suited for this purpose. Other IgG isotypes can be engineered accordingly to establish a ND property. A striking example of altering the activity of &#946; cell-specific Teff is observed with the application of ND anti-CD4 and -CD8&#945; Ab. A short-course of ND anti-CD4 and -CD8&#945; Ab induces remission in the majority of new onset diabetic NOD mice without affecting systemic T cell numbers (<xref rid="B128" ref-type="bibr">128</xref>&#8211;<xref rid="B131" ref-type="bibr">131</xref>). Induction of remission is due to Ab-mediated crosslinking of the CD4 and CD8 molecules, which reduces TCR signaling as well as upregulates additional signaling pathways (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B131" ref-type="bibr">131</xref>&#8211;<xref rid="B133" ref-type="bibr">133</xref>). The result is suppressed expression of proinflammatory cytokines by Teff combined with the induction of a promigratory phenotype that drives pancreatic egress of Teff (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B133" ref-type="bibr">133</xref>).</p><p>ND Ab and immunoglobulin (Ig) fusion molecules can also serve to block the function of key surface effector molecules. For instance, CTLA-4-Ig (Abatacept)-mediated blockade of the CD80 and CD86 co-stimulatory molecules inhibits APC function and alters the Teff pool in recent onset T1D patients. Abatacept therapy administered monthly for 24&#8201;months extends &#946; cell function up to 30&#8201;months (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). Examination of peripheral blood shows a decrease in the central memory CD4<sup>+</sup> T cell population with a concomitant increase in na&#239;ve T cells in Abatacept-treated individuals, supporting the notion that Teff expansion is limited (<xref rid="B135" ref-type="bibr">135</xref>).</p><p>Inhibiting cytotoxic pathways with ND blocking Ab offer another option to protect &#946; cell viability. NOD mice deficient in Fas lack islet-infiltrating effector cells and fail to develop T1D (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Ab blockade of FasL between 2 and 4&#8201;weeks of age prevents T1D in NOD mice. Interestingly, FasL blockade results in the presence of protective IL-10-producing B cells in the pancreas of NOD mice after treatment (<xref rid="B138" ref-type="bibr">138</xref>). These results suggest the targeting the Fas&#8211;FasL pathway may be a viable therapeutic avenue for the treatment of clinical T1D.</p><p>In addition to directly targeting immune effector cells, Ab or Ig-fusion molecules have been used to neutralize secreted effector molecules, such as proinflammatory cytokines. Neutralization of TNF&#945; with several antagonists including mAb (infliximab, adalimumab) and a recombinant TNF&#945; receptor fusion protein, etanercept, have been widely used to treat the autoimmunity driving RA (<xref rid="B139" ref-type="bibr">139</xref>). Although TNF&#945; is directly cytotoxic to &#946; cells, its role in the pathogenesis of T1D is controversial. In NOD mice, for instance, TNF&#945; accelerates the progression of &#946; cell autoimmunity when given at a young but not older age (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). In a 24-week clinical study, anti-TNF&#945; therapy in human T1D patients was seen to reduce levels of glycated hemoglobin A1C (HbA1c), a marker indicative of blood glucose values over a 3-month period, as well as increase C-peptide levels suggesting preservation of &#946; cell function (<xref rid="B142" ref-type="bibr">142</xref>). In a case report, treatment with infliximab was also found to reduce HbA1c levels, increase insulin secretion, and alleviate insulin resistance in a T1D patient also diagnosed with Crohn&#8217;s disease (<xref rid="B143" ref-type="bibr">143</xref>). Anti-TNF&#945; therapy, however, fails to prevent the development of T1D in at-risk patients, and may in fact accelerate disease progression (<xref rid="B144" ref-type="bibr">144</xref>). These results further underscore how efficacy (or lack of) is dependent on the stage of disease progression at which a given therapeutic is administered.</p><p>IL-21 is an appealing cytokine to target and suppress &#946; cell autoimmunity. IL-21 is chiefly produced by T follicular helper cells (Tfh) and Th17&#8201;cells, and has diverse roles that include regulating B cell and CD8<sup>+</sup> Teff function (<xref rid="B145" ref-type="bibr">145</xref>&#8211;<xref rid="B147" ref-type="bibr">147</xref>). The emerging role for both Tfh and Th17&#8201;cells in the progression of T1D, and the protective phenotype seen in NOD mice deficient of IL-21 suggests that neutralizing human IL-21 is a promising approach (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B148" ref-type="bibr">148</xref>&#8211;<xref rid="B152" ref-type="bibr">152</xref>). Indeed, neutralization of IL-21 with an IL-21R-Ig prevents diabetes in NOD mice (<xref rid="B153" ref-type="bibr">153</xref>).</p></sec><sec id="S4-2"><title>Cytokine-Based Immunotherapies</title><p>Administration of cytokines offers an approach to reestablish peripheral immunoregulation and &#946; cell tolerance. One such strategy currently being investigated is administration of low dose IL-2 (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B154" ref-type="bibr">154</xref>&#8211;<xref rid="B156" ref-type="bibr">156</xref>). Conventional CD4<sup>+</sup> and CD8<sup>+</sup> T cells but not Foxp3<sup>+</sup>Treg are producers of IL-2, which plays a central role in driving both pro- and anti-inflammatory responses (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>). IL-2 for instance is needed for conventional T cell activation and expansion, and IL-2 drives proinflammatory responses by other immune effectors (<xref rid="B158" ref-type="bibr">158</xref>). IL-2 also plays an essential role in Foxp3<sup>+</sup> Treg survival, expansion, and suppressor function (<xref rid="B159" ref-type="bibr">159</xref>&#8211;<xref rid="B161" ref-type="bibr">161</xref>). Constitutive expression of the high affinity IL-2R (CD25) allows Foxp3<sup>+</sup>Treg to out-compete conventional T cells for limiting amounts of IL-2. The latter provides rationale for using low dose IL-2 to preferentially affect Foxp3<sup>+</sup>Treg versus conventional T cells (<xref rid="B154" ref-type="bibr">154</xref>). Indeed, low dose IL-2 has been effective in the clinic for the treatment of graft-versus-host disease, and systemic vasculitis (<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). In NOD mice, low-dose IL-2 prevents clinical onset and reverses diabetes <italic toggle="yes">via</italic> an expanded pool of Foxp3<sup>+</sup> Treg in the islets and draining pancreatic lymph nodes (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B164" ref-type="bibr">164</xref>, <xref rid="B165" ref-type="bibr">165</xref>). Similarly, low-dose IL-2 in combination with rapamycin in recent onset T1D patients increases the frequency of Foxp3<sup>+</sup>Treg in blood (<xref rid="B166" ref-type="bibr">166</xref>). However, these patients also exhibit an accelerated rate of &#946; cell loss (<xref rid="B166" ref-type="bibr">166</xref>), suggesting an enhanced pathogenic response, and highlighting the key problem of administering a cytokine with pleiotropic effects (<xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>).</p><p>Different strategies are being developed to enhance the efficacy of IL-2 (and other cytokines), while avoiding unwanted systemic effects (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>). One approach is to promote selective binding of IL-2 to Foxp3<sup>+</sup>Treg <italic toggle="yes">via</italic> IL-2-Ab complexes (IL-2C) (<xref rid="B170" ref-type="bibr">170</xref>&#8211;<xref rid="B172" ref-type="bibr">172</xref>). Targeting particular epitopes on IL-2 with anti-IL-2 Ab can favor binding to the high affinity IL-2R constitutively expressed by Foxp3<sup>+</sup>Treg (<xref rid="B173" ref-type="bibr">173</xref>). Administration of IL-2C readily expands Foxp3<sup>+</sup>Treg in mice and prevents autoimmunity (<xref rid="B170" ref-type="bibr">170</xref>&#8211;<xref rid="B172" ref-type="bibr">172</xref>). While promising, polyclonal expansion of Foxp3<sup>+</sup>Treg by IL-2C may compromise protective immunity against pathogens.</p><p>An additional strategy to minimize the systemic effects of IL-2 while expanding &#946; cell-specific Foxp3<sup>+</sup>Treg is to target cytokine expression to &#946; cells <italic toggle="yes">in vivo</italic>. Adeno-associated virus (AAV) vectors have been used to deliver and target expression of an insulin promoter-driven IL-2 transgene (AAViP-IL2) to &#946; cells <italic toggle="yes">in vivo</italic> (<xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B174" ref-type="bibr">174</xref>). In general, AAV vectors are appealing for <italic toggle="yes">in vivo</italic> gene delivery due to limited immunogenicity, lack of integration into the genome, and efficient transduction of non-proliferating cells (<xref rid="B175" ref-type="bibr">175</xref>). Notably, treatment of NOD mice at a late preclinical T1D stage with AAViP-IL2 results in the expansion of islet-resident Foxp3<sup>+</sup>Treg, suppression of &#946; cell-specific Teff, and prevention of diabetes onset (<xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B74" ref-type="bibr">74</xref>). AAV vectors can be further exploited by co-delivering genes encoding other anti-inflammatory cytokines (e.g., IL-10, TGF&#946;1, and IL-35) and/or pro-survival proteins to enhance both the tolerogenic effect and maintenance of &#946; cell mass <italic toggle="yes">in vivo</italic> (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B176" ref-type="bibr">176</xref>&#8211;<xref rid="B179" ref-type="bibr">179</xref>).</p></sec><sec id="S4-3"><title>Foxp3<sup>+</sup>Treg-Mediated Therapy</title><p>An alternative strategy to manipulate the Foxp3<sup>+</sup>Treg population <italic toggle="yes">in vivo</italic> is to transfer Foxp3<sup>+</sup>Treg that have been expanded <italic toggle="yes">in vitro</italic> (<xref rid="B180" ref-type="bibr">180</xref>&#8211;<xref rid="B182" ref-type="bibr">182</xref>). The approach is effective in preventing diabetes onset in NOD mice (<xref rid="B183" ref-type="bibr">183</xref>). However, <italic toggle="yes">in vitro</italic> expansion of a homogeneous and stable pool of Foxp3<sup>+</sup>Treg, particularly when starting from relatively few cells, has been technically difficult. Expansion protocols are being devised using drugs such as rapamycin to prevent outgrowth of Teff, as well as DNA methyltransferase and histone deacetylase inhibitors to enhance Foxp3<sup>+</sup>Treg stability (<xref rid="B184" ref-type="bibr">184</xref>, <xref rid="B185" ref-type="bibr">185</xref>). Despite these hurdles, clinical studies have shown Foxp3<sup>+</sup>Treg therapy is well tolerated and therapeutic efficacy is observed for various diseases (<xref rid="B180" ref-type="bibr">180</xref>, <xref rid="B181" ref-type="bibr">181</xref>). Furthermore, a phase I trial has demonstrated that <italic toggle="yes">in vitro</italic>-expanded Foxp3<sup>+</sup>Treg persist long-term and exhibit a stable phenotype when transferred back into T1D subjects (<xref rid="B180" ref-type="bibr">180</xref>). Notably, loss of C peptide is also limited in some patients. These results provide justification for additional clinical studies to directly assess the efficacy of Foxp3<sup>+</sup>Treg transfer for T1D treatment.</p></sec><sec id="S4-4"><title>Microbiome Interventions in T1D</title><p>In recent years, the importance of the gut microbiota in maintaining the normal function of the immune system has emerged (<xref rid="B186" ref-type="bibr">186</xref>). Reports have documented that changes in gut microbiota can markedly influence T1D development, and that differences in the colonizing microflora contributes to variations in T1D onset among NOD mouse colonies (<xref rid="B187" ref-type="bibr">187</xref>, <xref rid="B188" ref-type="bibr">188</xref>). Toll-like receptors (TLRs) play a crucial role in the innate immune system&#8217;s recognition of common bacterial and viral components. TLR signaling triggers APC maturation and production of proinflammatory mediators (<xref rid="B189" ref-type="bibr">189</xref>). One of the major TLR signaling adaptor molecules driving APC maturation is MyD88, which activates several downstream signaling pathways (<xref rid="B190" ref-type="bibr">190</xref>). NOD mice lacking MyD88 expression and housed under normal specific-pathogen-free conditions exhibit a reduced T1D incidence. In contrast, MyD88-deficient NOD mice housed in germ-free conditions develop robust diabetes (<xref rid="B16" ref-type="bibr">16</xref>). Interestingly sex differences in the gut microbiota also influence T1D susceptibility. For example, young female NOD mice receiving gut microbiota from male NOD mice exhibit a reduced T1D incidence (<xref rid="B191" ref-type="bibr">191</xref>). These results demonstrate that the gut microbiota can have a protective role against autoimmunity, and specifically T1D. Furthermore, differences in the biodiversity of the gut microbiome are seen between T1D patients and healthy individuals (<xref rid="B192" ref-type="bibr">192</xref>&#8211;<xref rid="B196" ref-type="bibr">196</xref>). Similarly, the microbiome within the gut of T1D infants fails to diversify during development in comparison to healthy individuals, potentially due to hyperglycemia (<xref rid="B197" ref-type="bibr">197</xref>). Here, changes in the production of microbial metabolites such as short-chain fatty acids found in the colonic lumen and peripheral blood are thought to impact immunoregulatory networks. Indeed, a recent study showed that diets that enhance production of acetate and butyrate by the gut microbiome, effectively prevent diabetes in NOD mice (<xref rid="B198" ref-type="bibr">198</xref>). Increased acetate is seen to reduce &#946; cell-specific Teff, whereas elevated butyrate expands Foxp3<sup>+</sup>Treg. Together these results indicate an association between modified gut microbiota and compromised self-tolerance. Manipulating the gut microbiota may prove to be an effective adjuvant therapy to limit the progression of &#946; cell autoimmunity in at-risk individuals.</p></sec></sec><sec id="S5"><title>Antigen-Dependent Immunotherapies</title><p>The goal of antigen-based therapies is to selectively tolerize the autoreactive Teff pool and induce or expand autoantigen-specific Treg (<xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B202" ref-type="bibr">202</xref>). The approach is appealing, since &#946; cell antigen vaccination is expected to have no effect on acquired immunity. Teff are tolerized <italic toggle="yes">via</italic> whole antigen or peptide by various mechanisms, including: (i) clonal anergy, (ii) clonal deletion, or (iii) exhaustion. This has classically been achieved by administration of high doses of soluble antigen or peptide. On the other hand, antigen vaccination has been used to induce differentiation of na&#239;ve &#946; cell-specific T cells into aTreg, including iFoxp3<sup>+</sup>Treg. Depending on the conditions of antigen vaccination, distinct subsets of aTreg can be induced. Expanding the aTreg pool is advantageous, since local cytokine-mediated suppression is independent of Teff antigen-specificity; this bystander-mediated suppression also can downregulate the activity of proinflammatory APC. Success of either tolerizing Teff or inducing/expanding Treg is dictated by multiple factors including dose, the frequency, and route of antigen vaccination. Also important is the context in which the antigen is delivered. Antigen administration in the context of an adjuvant, microparticles, or DC can significantly alter the nature of the T cell response. The most critical factor determining efficacy, however, is the identity of the autoantigen (or peptide) used for vaccination. To effectively block the progression of &#946; cell autoimmunity, prevalent, or immunodominant Teff clonotypes need to be targeted. Ongoing efforts defining the specificity of islet-resident Teff are expected to identify immunodominant Teff clonotypes (<xref rid="B31" ref-type="bibr">31</xref>). Furthermore, promising antigen-based immunotherapies are exploiting advancements in targeted drug delivery systems to effectively tolerize Teff and promote Treg-mediated suppression.</p><sec id="S5-1"><title>&#946; Cell-Autoantigen Vaccination</title><p>Early clinical studies have highlighted the difficulty in establishing a protective, &#946; cell-specific T cell response <italic toggle="yes">via</italic> autoantigen vaccination (<xref rid="B203" ref-type="bibr">203</xref>). The Diabetes Prevention Trial-type 1 tested parenteral insulin delivery <italic toggle="yes">via</italic> intravenous (i.v.), subcutaneous (s.c.), and oral routes in at-risk individuals (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B204" ref-type="bibr">204</xref>&#8211;<xref rid="B206" ref-type="bibr">206</xref>). No significant difference, however, was detected in the frequency and onset of diabetes in the treatment and control cohorts. Similarly, phase II and III studies of s.c. vaccination of aluminum hydroxide (alum)-formulated GAD65 to new onset T1D patients had no marked effect on C-peptide secretion over time (<xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>). Alum as an adjuvant is included due to a potent capacity to induce IL-4-secreting Th2 cells, which in turn can block the differentiation of pathogenic IFN&#947;-producing Teff (<xref rid="B209" ref-type="bibr">209</xref>, <xref rid="B210" ref-type="bibr">210</xref>).</p><p>Additional studies have tested insulin and proinsulin peptides to restore &#946; cell tolerance in human T1D patients. An altered-peptide ligand of the insulin B chain 9&#8211;23 epitope administered s.c. to recent onset T1D subjects reduces peptide-specific IFN&#947;-secreting Teff, while elevating Th2-like aTreg (<xref rid="B211" ref-type="bibr">211</xref>, <xref rid="B212" ref-type="bibr">212</xref>). Nevertheless, no clinical benefit was detected, suggesting that altering insulin B chain-specific Teff reactivity alone is insufficient to induce robust &#946; cell tolerance. Clinical trials assessing intradermal vaccination of a natural peptide derived from proinsulin (C19-A3) have also been carried out (<xref rid="B213" ref-type="bibr">213</xref>, <xref rid="B214" ref-type="bibr">214</xref>). Vaccination with low (30ug) versus high (300&#8201;&#181;g) doses of C19-A3 increases the frequency of peptide-specific CD4<sup>+</sup> Tr1 cells in long-standing T1D subjects (<xref rid="B213" ref-type="bibr">213</xref>). A similar increase in CD4<sup>+</sup> Tr1 cells is detected in newly diagnosed T1D subjects vaccinated with C19-A3 (<xref rid="B214" ref-type="bibr">214</xref>). Notably, FOXP3<sup>+</sup> Treg are also increased, and evidence suggests that residual &#946; cell function is preserved in some individuals (<xref rid="B214" ref-type="bibr">214</xref>). Treatment with a pool of peptides derived from additional &#946; cell autoantigens may promote a more robust tolerogenic effect on Teff, as well as enhance induction and/or expansion of the aTreg pool.</p></sec><sec id="S5-2"><title>Strategies to Enhance the Efficacy of &#946; Cell-Autoantigen Vaccination</title><p>As noted above the context of autoantigen vaccination is critical for determining the nature and magnitude of the induced T cell response, and in turn therapeutic efficacy. Various strategies are being developed to better &#8220;tailor&#8221; the antigen-specific T cell response. One such approach has been the application of plasmid DNA (pDNA) vaccination. Injection of soluble pDNA or <italic toggle="yes">via</italic> gene gun delivered pDNA-coated particles results in significant levels of transgene expression lasting several weeks <italic toggle="yes">in vivo</italic> (<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B216" ref-type="bibr">216</xref>). Co-vaccination of pDNA encoding &#946; cell autoantigens and anti-inflammatory cytokines both induces protective &#946; cell-specific aTreg, and prevents diabetes onset in NOD mice (<xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B217" ref-type="bibr">217</xref>&#8211;<xref rid="B220" ref-type="bibr">220</xref>). In a T1D clinical trial, patients received intramuscular injections of pDNA encoding proinsulin over a 12-week period. C-peptide levels were maintained up to 3&#8201;months after treatment, which corresponded with a reduced frequency of proinsulin-specific CD8<sup>+</sup> T cells in peripheral blood (<xref rid="B221" ref-type="bibr">221</xref>). Notably, the frequency of CD8<sup>+</sup> T cells specific for foreign antigen remained unperturbed, illustrating a key strength of &#946; cell-autoantigen vaccination.</p><p>An additional approach to enhance the efficacy of &#946; cell-autoantigen vaccines is the use of small molecule particles (<xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B223" ref-type="bibr">223</xref>). Typically, injected &#946; cell antigens and other soluble reagents have a short half-life <italic toggle="yes">in vivo</italic>, which can be greatly enhanced by encapsulation into a particle. Particles are generated using different compounds, including poly(lactide-co-glycolide) and acetalated dextran (<xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B224" ref-type="bibr">224</xref>). The particle size and composition can be readily manipulated to determine cellular uptake and cargo release <italic toggle="yes">in vivo</italic> (<xref rid="B225" ref-type="bibr">225</xref>). Some studies have included cell-specific Ab or ligands to target particles to a desired cell population, and avoid off-target effects (<xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B226" ref-type="bibr">226</xref>&#8211;<xref rid="B228" ref-type="bibr">228</xref>). However, most treatments utilize the natural phagocytic function of DC and macrophages to engulf the injected particles. In this way, a tolerogenic APC phenotype can also be established <italic toggle="yes">in vivo</italic> by encapsulating various immunomodulatory agents such as the aryl hydrocarbon receptor ligand 2-(1&#8242;H-indole-3&#8242;-carbonyl)-thiazole-4-carboxylic acid methyl ester, rapamycin, dexamethasone, cytokines, and/or antisense oligodeoxynucleotides (<xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B223" ref-type="bibr">223</xref>, <xref rid="B229" ref-type="bibr">229</xref>&#8211;<xref rid="B232" ref-type="bibr">232</xref>). These APC upon presenting the loaded antigen more readily tolerize Teff and/or induce aTreg (<xref rid="B229" ref-type="bibr">229</xref>&#8211;<xref rid="B232" ref-type="bibr">232</xref>).</p><p>As opposed to delivering a cargo to APC, nanoparticles have also been used as surrogate APC (<xref rid="B233" ref-type="bibr">233</xref>, <xref rid="B234" ref-type="bibr">234</xref>). Here the surface of nanoparticles is complexed with MHC class II (MHCII) molecules tethered to a &#946; cell-derived peptide (<xref rid="B234" ref-type="bibr">234</xref>). These MHCII-peptide-coated nanoparticles promote differentiation of CD4<sup>+</sup> Teff into Tr1 cells that are readily expanded, and in turn drive diabetes remission in NOD mice (<xref rid="B234" ref-type="bibr">234</xref>). Another approach has exploited the tolerogenic properties of apoptotic cells. Uptake of apoptotic bodies by immature DC and macrophages blocks subsequent APC maturation and promotes upregulation of TGF&#946;1 (<xref rid="B235" ref-type="bibr">235</xref>). Accordingly, i.v. injection of 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide (ECDI) fixed splenocytes loaded with autoantigen suppresses experimental autoimmune encephalomyelitis, a murine model of multiple sclerosis (MS) (<xref rid="B236" ref-type="bibr">236</xref>). Currently, this approach is being tested in clinical trials in which MS patients receive an i.v. transfusion of ECDI-fixed peripheral blood mononuclear cells loaded with MS-relevant peptides recognized by CD4<sup>+</sup> T cells (<xref rid="B237" ref-type="bibr">237</xref>, <xref rid="B238" ref-type="bibr">238</xref>).</p></sec></sec><sec id="S6"><title>Summary</title><p>Type 1 diabetes is a complex disease driven by pathogenic adaptive and innate responses leading to the dysfunction and destruction of &#946; cells (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>). Although disease immunopathology is heterogeneous, T cells are considered to be the key mediators of &#946; cell destruction/dysfunction for the majority of cases of human T1D (<xref rid="B57" ref-type="bibr">57</xref>). Consequently, T cells have been the focus of most strategies of immunotherapy. Suppression of pathogenic &#946; cell-specific T cell reactivity in the islets long-term, while preserving acquired immunity is the ultimate goal for a given immunotherapy (Figure <xref ref-type="fig" rid="F1">1</xref>). Achieving this goal in the clinic, however, has been elusive. To date, the most effective strategies have been broadly acting on the majority if not all T cells although protection has also been demonstrated by targeting B cells (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B239" ref-type="bibr">239</xref>). Efficacy, however, is short-lived. Furthermore, systemic depletion and unwanted effects on protective immunity seen with anti-CD3 mAb therapy for instance, limit dosing and repeated application for efforts to extend &#946; cell protection. On the other hand, antigen-based immunotherapy, such as &#946; cell protein/peptide or particle vaccination, must contend with what is likely to be a high degree of diversity in the &#946; cell-specific T cell response among T1D individuals and T1D subsets (<xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B201" ref-type="bibr">201</xref>). Therefore, the ability to tolerize a sufficient number of disease-driving self-reactive T cell clones residing in the islets will be challenging. The most effective approach may reside in combining strategies functioning <italic toggle="yes">via</italic> distinct mechanisms. ND Ab specific for CD4 and CD8, for example, can be used to purge pathogenic Teff residing in the islets (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B133" ref-type="bibr">133</xref>). This would then be followed by an antigen-based strategy in which the need to establish a sufficiently sized pool of aTreg becomes less stringent. A novel combinatorial approach recently described utilizes IL-2C and MHC class II-peptide tetramers. This combination expands the frequency of Foxp3<sup>+</sup>Treg in a peptide-specific manner that results in prevention of diabetes in NOD mice (<xref rid="B240" ref-type="bibr">240</xref>).</p><p>Further studies defining common biomarkers of T1D will be critical in designing treatment protocols for individual patients, as well as for monitoring the effects of a given immunotherapy. Current advancements in large-scale genomic and proteomic analyses are making identification of these types of markers a reality, in addition to &#8220;matching&#8221; at risk or T1D patients with the most appropriate immunotherapy.</p></sec><sec id="S7"><title>Author Contributions</title><p>CJK, MC, QK, and RMT contributed to the preparation of the review article.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by National Institutes of Health grants R01DK100256 and R01DK1035486 (RMT) and T32AI007273 (MC).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bach</surname><given-names>JF</given-names></name></person-group>. <article-title>Insulin-dependent diabetes mellitus as an autoimmune disease</article-title>. <source>Endocr Rev</source> (<year>1994</year>) <volume>15</volume>(<issue>4</issue>):<fpage>516</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1210/edrv-15-4-516</pub-id><pub-id pub-id-type="pmid">7988484</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name><name name-style="western"><surname>McDevitt</surname><given-names>H</given-names></name></person-group><article-title>Insulin-dependent diabetes mellitus</article-title>. <source>Cell</source> (<year>1996</year>) <volume>85</volume>(<issue>3</issue>):<fpage>291</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81106-X</pub-id><pub-id pub-id-type="pmid">8616883</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenbarth</surname><given-names>GS</given-names></name></person-group><article-title>Type 1 diabetes: molecular, cellular and clinical immunology</article-title>. <source>Adv Exp Med Biol</source> (<year>2004</year>) <volume>552</volume>:<fpage>306</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">15622970</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name></person-group>. <article-title>The NOD mouse: a model of immune dysregulation</article-title>. <source>Annu Rev Immunol</source> (<year>2005</year>) <volume>23</volume>:<fpage>447</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115643</pub-id><pub-id pub-id-type="pmid">15771578</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>JC</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>DG</given-names></name><name name-style="western"><surname>Concannon</surname><given-names>P</given-names></name><name name-style="western"><surname>Akolkar</surname><given-names>B</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>JD</given-names></name><name name-style="western"><surname>Erlich</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes</article-title>. <source>Nat Genet</source> (<year>2009</year>) <volume>41</volume>(<issue>6</issue>):<fpage>703</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/ng.381</pub-id><pub-id pub-id-type="pmid">19430480</pub-id><pub-id pub-id-type="pmcid">PMC2889014</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pociot</surname><given-names>F</given-names></name><name name-style="western"><surname>Akolkar</surname><given-names>B</given-names></name><name name-style="western"><surname>Concannon</surname><given-names>P</given-names></name><name name-style="western"><surname>Erlich</surname><given-names>HA</given-names></name><name name-style="western"><surname>Julier</surname><given-names>C</given-names></name><name name-style="western"><surname>Morahan</surname><given-names>G</given-names></name><etal/></person-group><article-title>Genetics of type 1 diabetes: what&#8217;s next?</article-title><source>Diabetes</source> (<year>2010</year>) <volume>59</volume>(<issue>7</issue>):<fpage>1561</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.2337/db10-0076</pub-id><pub-id pub-id-type="pmid">20587799</pub-id><pub-id pub-id-type="pmcid">PMC2889752</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noble</surname><given-names>JA</given-names></name><name name-style="western"><surname>Erlich</surname><given-names>HA</given-names></name></person-group>. <article-title>Genetics of type 1 diabetes</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2012</year>) <volume>2</volume>(<issue>1</issue>):<fpage>a007732</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a007732</pub-id><pub-id pub-id-type="pmid">22315720</pub-id><pub-id pub-id-type="pmcid">PMC3253030</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WM</given-names></name><name name-style="western"><surname>Burren</surname><given-names>O</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Quinlan</surname><given-names>AR</given-names></name><name name-style="western"><surname>Mychaleckyj</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers</article-title>. <source>Nat Genet</source> (<year>2015</year>) <volume>47</volume>(<issue>4</issue>):<fpage>381</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/ng.3245</pub-id><pub-id pub-id-type="pmid">25751624</pub-id><pub-id pub-id-type="pmcid">PMC4380767</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Op de Beeck</surname><given-names>A</given-names></name><name name-style="western"><surname>Eizirik</surname><given-names>DL</given-names></name></person-group><article-title>Viral infections in type 1 diabetes mellitus &#8211; why the beta cells?</article-title><source>Nat Rev Endocrinol</source> (<year>2016</year>) <volume>12</volume>(<issue>5</issue>):<fpage>263</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1038/nrendo.2016.30</pub-id><pub-id pub-id-type="pmid">27020257</pub-id><pub-id pub-id-type="pmcid">PMC5348720</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laitinen</surname><given-names>OH</given-names></name><name name-style="western"><surname>Honkanen</surname><given-names>H</given-names></name><name name-style="western"><surname>Pakkanen</surname><given-names>O</given-names></name><name name-style="western"><surname>Oikarinen</surname><given-names>S</given-names></name><name name-style="western"><surname>Hankaniemi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Huhtala</surname><given-names>H</given-names></name><etal/></person-group><article-title>Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2014</year>) <volume>63</volume>(<issue>2</issue>):<fpage>446</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.2337/db13-0619</pub-id><pub-id pub-id-type="pmid">23974921</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oikarinen</surname><given-names>S</given-names></name><name name-style="western"><surname>Tauriainen</surname><given-names>S</given-names></name><name name-style="western"><surname>Hober</surname><given-names>D</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>B</given-names></name><name name-style="western"><surname>Vazeou</surname><given-names>A</given-names></name><name name-style="western"><surname>Sioofy-Khojine</surname><given-names>A</given-names></name><etal/></person-group><article-title>Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2014</year>) <volume>63</volume>(<issue>2</issue>):<fpage>655</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.2337/db13-0620</pub-id><pub-id pub-id-type="pmid">24009257</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name></person-group>. <article-title>The pathogenesis and natural history of type 1 diabetes</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2012</year>) <volume>2</volume>(<issue>11</issue>).<pub-id pub-id-type="doi">10.1101/cshperspect.a007641</pub-id><pub-id pub-id-type="pmid">23125199</pub-id><pub-id pub-id-type="pmcid">PMC3543105</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsarou</surname><given-names>A</given-names></name><name name-style="western"><surname>Gudbjornsdottir</surname><given-names>S</given-names></name><name name-style="western"><surname>Rawshani</surname><given-names>A</given-names></name><name name-style="western"><surname>Dabelea</surname><given-names>D</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>E</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Type 1 diabetes mellitus</article-title>. <source>Nat Rev Dis Primers</source> (<year>2017</year>) <volume>3</volume>:<fpage>17016</fpage>.<pub-id pub-id-type="doi">10.1038/nrdp.2017.16</pub-id><pub-id pub-id-type="pmid">28358037</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knip</surname><given-names>M</given-names></name><name name-style="western"><surname>Siljander</surname><given-names>H</given-names></name></person-group>. <article-title>The role of the intestinal microbiota in type 1 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source> (<year>2016</year>) <volume>12</volume>(<issue>3</issue>):<fpage>154</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1038/nrendo.2015.218</pub-id><pub-id pub-id-type="pmid">26729037</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaarala</surname><given-names>O</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Neu</surname><given-names>J</given-names></name></person-group><article-title>The &#8220;perfect storm&#8221; for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity</article-title>. <source>Diabetes</source> (<year>2008</year>) <volume>57</volume>(<issue>10</issue>):<fpage>2555</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.2337/db08-0331</pub-id><pub-id pub-id-type="pmid">18820210</pub-id><pub-id pub-id-type="pmcid">PMC2551660</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>L</given-names></name><name name-style="western"><surname>Ley</surname><given-names>RE</given-names></name><name name-style="western"><surname>Volchkov</surname><given-names>PY</given-names></name><name name-style="western"><surname>Stranges</surname><given-names>PB</given-names></name><name name-style="western"><surname>Avanesyan</surname><given-names>L</given-names></name><name name-style="western"><surname>Stonebraker</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Innate immunity and intestinal microbiota in the development of type 1 diabetes</article-title>. <source>Nature</source> (<year>2008</year>) <volume>455</volume>(<issue>7216</issue>):<fpage>1109</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1038/nature07336</pub-id><pub-id pub-id-type="pmid">18806780</pub-id><pub-id pub-id-type="pmcid">PMC2574766</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nerup</surname><given-names>J</given-names></name><name name-style="western"><surname>Platz</surname><given-names>P</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>OO</given-names></name><name name-style="western"><surname>Christy</surname><given-names>M</given-names></name><name name-style="western"><surname>Lyngsoe</surname><given-names>J</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>JE</given-names></name><etal/></person-group><article-title>HL-A antigens and diabetes mellitus</article-title>. <source>Lancet</source> (<year>1974</year>) <volume>2</volume>(<issue>7885</issue>):<fpage>864</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(74)91201-X</pub-id><pub-id pub-id-type="pmid">4137711</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bottini</surname><given-names>N</given-names></name><name name-style="western"><surname>Musumeci</surname><given-names>L</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahmouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Nika</surname><given-names>K</given-names></name><name name-style="western"><surname>Rostamkhani</surname><given-names>M</given-names></name><etal/></person-group><article-title>A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes</article-title>. <source>Nat Genet</source> (<year>2004</year>) <volume>36</volume>(<issue>4</issue>):<fpage>337</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/ng1323</pub-id><pub-id pub-id-type="pmid">15004560</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smyth</surname><given-names>D</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>JD</given-names></name><name name-style="western"><surname>Collins</surname><given-names>JE</given-names></name><name name-style="western"><surname>Heward</surname><given-names>JM</given-names></name><name name-style="western"><surname>Franklyn</surname><given-names>JA</given-names></name><name name-style="western"><surname>Howson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus</article-title>. <source>Diabetes</source> (<year>2004</year>) <volume>53</volume>(<issue>11</issue>):<fpage>3020</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.53.11.3020</pub-id><pub-id pub-id-type="pmid">15504986</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nistico</surname><given-names>L</given-names></name><name name-style="western"><surname>Buzzetti</surname><given-names>R</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>LE</given-names></name><name name-style="western"><surname>Van der Auwera</surname><given-names>B</given-names></name><name name-style="western"><surname>Giovannini</surname><given-names>C</given-names></name><name name-style="western"><surname>Bosi</surname><given-names>E</given-names></name><etal/></person-group><article-title>The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry</article-title>. <source>Hum Mol Genet</source> (<year>1996</year>) <volume>5</volume>(<issue>7</issue>):<fpage>1075</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1093/hmg/5.7.1075</pub-id><pub-id pub-id-type="pmid">8817351</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>H</given-names></name><name name-style="western"><surname>Howson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>L</given-names></name><name name-style="western"><surname>Heward</surname><given-names>J</given-names></name><name name-style="western"><surname>Snook</surname><given-names>H</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease</article-title>. <source>Nature</source> (<year>2003</year>) <volume>423</volume>(<issue>6939</issue>):<fpage>506</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1038/nature01621</pub-id><pub-id pub-id-type="pmid">12724780</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Field</surname><given-names>LL</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pociot</surname><given-names>F</given-names></name><name name-style="western"><surname>Nerup</surname><given-names>J</given-names></name><name name-style="western"><surname>Tobias</surname><given-names>R</given-names></name><name name-style="western"><surname>Bonnevie-Nielsen</surname><given-names>V</given-names></name></person-group>. <article-title>Evidence for a locus (IDDM16) in the immunoglobulin heavy chain region on chromosome 14q32.3 producing susceptibility to type 1 diabetes</article-title>. <source>Genes Immun</source> (<year>2002</year>) <volume>3</volume>(<issue>6</issue>):<fpage>338</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/sj.gene.6363857</pub-id><pub-id pub-id-type="pmid">12209360</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morahan</surname><given-names>G</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ymer</surname><given-names>SI</given-names></name><name name-style="western"><surname>Cancilla</surname><given-names>MR</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>K</given-names></name><name name-style="western"><surname>Dabadghao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele</article-title>. <source>Nat Genet</source> (<year>2001</year>) <volume>27</volume>(<issue>2</issue>):<fpage>218</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1038/84872</pub-id><pub-id pub-id-type="pmid">11175794</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>M</given-names></name><name name-style="western"><surname>Kroger</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>RM</given-names></name></person-group>. <article-title>Type 1 diabetes: a chronic anti-self-inflammatory response</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>1898</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01898</pub-id><pub-id pub-id-type="pmid">29312356</pub-id><pub-id pub-id-type="pmcid">PMC5743904</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallone</surname><given-names>R</given-names></name><name name-style="western"><surname>Brezar</surname><given-names>V</given-names></name><name name-style="western"><surname>Boitard</surname><given-names>C</given-names></name></person-group>. <article-title>T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives</article-title>. <source>Clin Dev Immunol</source> (<year>2011</year>) <volume>2011</volume>:<fpage>513210</fpage>.<pub-id pub-id-type="doi">10.1155/2011/513210</pub-id><pub-id pub-id-type="pmid">21785617</pub-id><pub-id pub-id-type="pmcid">PMC3140193</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enee</surname><given-names>E</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Arnoux</surname><given-names>JB</given-names></name><name name-style="western"><surname>Barilleau</surname><given-names>E</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>C</given-names></name><etal/></person-group><article-title>ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>7</issue>):<fpage>1779</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.2337/db12-0071</pub-id><pub-id pub-id-type="pmid">22586580</pub-id><pub-id pub-id-type="pmcid">PMC3379659</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><name name-style="western"><surname>Donelan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>LJ</given-names></name></person-group>. <article-title>Novel autoantigens in type 1 diabetes</article-title>. <source>Am J Transl Res</source> (<year>2013</year>) <volume>5</volume>(<issue>4</issue>):<fpage>379</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">23724162</pub-id><pub-id pub-id-type="pmcid">PMC3665912</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name></person-group>. <article-title>Antigen targets of type 1 diabetes autoimmunity</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2012</year>) <volume>2</volume>(<issue>4</issue>):<fpage>a007781</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a007781</pub-id><pub-id pub-id-type="pmid">22474615</pub-id><pub-id pub-id-type="pmcid">PMC3312399</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michels</surname><given-names>AW</given-names></name><name name-style="western"><surname>Landry</surname><given-names>LG</given-names></name><name name-style="western"><surname>McDaniel</surname><given-names>KA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Islet-derived CD4 T cells targeting proinsulin in human autoimmune diabetes</article-title>. <source>Diabetes</source> (<year>2017</year>) <volume>66</volume>(<issue>3</issue>):<fpage>722</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.2337/db16-1025</pub-id><pub-id pub-id-type="pmid">27920090</pub-id><pub-id pub-id-type="pmcid">PMC5319719</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delong</surname><given-names>T</given-names></name><name name-style="western"><surname>Baker</surname><given-names>RL</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>G</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B</given-names></name><name name-style="western"><surname>Haskins</surname><given-names>K</given-names></name></person-group>. <article-title>Diabetogenic T-cell clones recognize an altered peptide of chromogranin A</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>12</issue>):<fpage>3239</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.2337/db12-0112</pub-id><pub-id pub-id-type="pmid">22912420</pub-id><pub-id pub-id-type="pmcid">PMC3501882</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babon</surname><given-names>JA</given-names></name><name name-style="western"><surname>DeNicola</surname><given-names>ME</given-names></name><name name-style="western"><surname>Blodgett</surname><given-names>DM</given-names></name><name name-style="western"><surname>Crevecoeur</surname><given-names>I</given-names></name><name name-style="western"><surname>Buttrick</surname><given-names>TS</given-names></name><name name-style="western"><surname>Maehr</surname><given-names>R</given-names></name><etal/></person-group><article-title>Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes</article-title>. <source>Nat Med</source> (<year>2016</year>) <volume>22</volume>(<issue>12</issue>):<fpage>1482</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nm.4203</pub-id><pub-id pub-id-type="pmid">27798614</pub-id><pub-id pub-id-type="pmcid">PMC5140746</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wiles</surname><given-names>TA</given-names></name><name name-style="western"><surname>Baker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>G</given-names></name><name name-style="western"><surname>Reisdorph</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion</article-title>. <source>Science</source> (<year>2016</year>) <volume>351</volume>(<issue>6274</issue>):<fpage>711</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1126/science.aad2791</pub-id><pub-id pub-id-type="pmid">26912858</pub-id><pub-id pub-id-type="pmcid">PMC4884646</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Jamison</surname><given-names>BL</given-names></name><name name-style="western"><surname>Wiles</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>RS</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>G</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B</given-names></name><etal/></person-group><article-title>CD4 T cells reactive to hybrid insulin peptides are indicators of disease activity in the NOD mouse</article-title>. <source>Diabetes</source> (<year>2018</year>) <volume>67</volume>(<issue>8</issue>):<fpage>db180200</fpage>.<pub-id pub-id-type="doi">10.2337/db18-0200</pub-id><pub-id pub-id-type="pmid">29976617</pub-id><pub-id pub-id-type="pmcid">PMC6110316</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiles</surname><given-names>TA</given-names></name><name name-style="western"><surname>Delong</surname><given-names>T</given-names></name><name name-style="western"><surname>Baker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>G</given-names></name><name name-style="western"><surname>Powell</surname><given-names>RL</given-names></name><etal/></person-group><article-title>An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse</article-title>. <source>J Autoimmun</source> (<year>2017</year>) <volume>78</volume>:<fpage>11</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2016.10.007</pub-id><pub-id pub-id-type="pmid">27802879</pub-id><pub-id pub-id-type="pmcid">PMC5337175</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>Kracht</surname><given-names>MJ</given-names></name><name name-style="western"><surname>van Lummel</surname><given-names>M</given-names></name><name name-style="western"><surname>Zaldumbide</surname><given-names>A</given-names></name></person-group>. <article-title>A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes</article-title>. <source>Curr Opin Immunol</source> (<year>2016</year>) <volume>43</volume>:<fpage>67</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2016.09.007</pub-id><pub-id pub-id-type="pmid">27723537</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kracht</surname><given-names>MJ</given-names></name><name name-style="western"><surname>van Lummel</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikolic</surname><given-names>T</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laban</surname><given-names>S</given-names></name><name name-style="western"><surname>van der Slik</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes</article-title>. <source>Nat Med</source> (<year>2017</year>) <volume>23</volume>(<issue>4</issue>):<fpage>501</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nm.4289</pub-id><pub-id pub-id-type="pmid">28263308</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phelps</surname><given-names>EA</given-names></name><name name-style="western"><surname>Cianciaruso</surname><given-names>C</given-names></name><name name-style="western"><surname>Michael</surname><given-names>IP</given-names></name><name name-style="western"><surname>Pasquier</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanaani</surname><given-names>J</given-names></name><name name-style="western"><surname>Nano</surname><given-names>R</given-names></name><etal/></person-group><article-title>Aberrant accumulation of the diabetes autoantigen GAD65 in Golgi membranes in conditions of ER stress and autoimmunity</article-title>. <source>Diabetes</source> (<year>2016</year>) <volume>65</volume>(<issue>9</issue>):<fpage>2686</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.2337/db16-0180</pub-id><pub-id pub-id-type="pmid">27284108</pub-id><pub-id pub-id-type="pmcid">PMC5001175</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eizirik</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sammeth</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouckenooghe</surname><given-names>T</given-names></name><name name-style="western"><surname>Bottu</surname><given-names>G</given-names></name><name name-style="western"><surname>Sisino</surname><given-names>G</given-names></name><name name-style="western"><surname>Igoillo-Esteve</surname><given-names>M</given-names></name><etal/></person-group><article-title>The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines</article-title>. <source>PLoS Genet</source> (<year>2012</year>) <volume>8</volume>(<issue>3</issue>):<fpage>e1002552</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pgen.1002552</pub-id><pub-id pub-id-type="pmid">22412385</pub-id><pub-id pub-id-type="pmcid">PMC3297576</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortis</surname><given-names>F</given-names></name><name name-style="western"><surname>Naamane</surname><given-names>N</given-names></name><name name-style="western"><surname>Flamez</surname><given-names>D</given-names></name><name name-style="western"><surname>Ladriere</surname><given-names>L</given-names></name><name name-style="western"><surname>Moore</surname><given-names>F</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells</article-title>. <source>Diabetes</source> (<year>2010</year>) <volume>59</volume>(<issue>2</issue>):<fpage>358</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.2337/db09-1159</pub-id><pub-id pub-id-type="pmid">19934004</pub-id><pub-id pub-id-type="pmcid">PMC2809955</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks-Worrell</surname><given-names>B</given-names></name><name name-style="western"><surname>Gersuk</surname><given-names>VH</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>JP</given-names></name></person-group>. <article-title>Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>(<issue>8</issue>):<fpage>5265</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.166.8.5265</pub-id><pub-id pub-id-type="pmid">11290812</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>S</given-names></name><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name></person-group>. <article-title>Proinsulin: a unique autoantigen triggering autoimmune diabetes</article-title>. <source>J Clin Invest</source> (<year>2006</year>) <volume>116</volume>(<issue>12</issue>):<fpage>3108</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1172/JCI30760</pub-id><pub-id pub-id-type="pmid">17143326</pub-id><pub-id pub-id-type="pmcid">PMC1679718</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Herrath</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanda</surname><given-names>S</given-names></name><name name-style="western"><surname>Herold</surname><given-names>K</given-names></name></person-group>. <article-title>Type 1 diabetes as a relapsing-remitting disease?</article-title><source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>12</issue>):<fpage>988</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1038/nri2192</pub-id><pub-id pub-id-type="pmid">17982429</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willcox</surname><given-names>A</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bone</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Foulis</surname><given-names>AK</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>NG</given-names></name></person-group>. <article-title>Analysis of islet inflammation in human type 1 diabetes</article-title>. <source>Clin Exp Immunol</source> (<year>2009</year>) <volume>155</volume>(<issue>2</issue>):<fpage>173</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03860.x</pub-id><pub-id pub-id-type="pmid">19128359</pub-id><pub-id pub-id-type="pmcid">PMC2675247</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></name></person-group>. <article-title>Autoreactive T cells in type 1 diabetes</article-title>. <source>J Clin Invest</source> (<year>2017</year>) <volume>127</volume>(<issue>8</issue>):<fpage>2881</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1172/JCI94549</pub-id><pub-id pub-id-type="pmid">28762987</pub-id><pub-id pub-id-type="pmcid">PMC5531393</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coppieters</surname><given-names>KT</given-names></name><name name-style="western"><surname>Dotta</surname><given-names>F</given-names></name><name name-style="western"><surname>Amirian</surname><given-names>N</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>PD</given-names></name><name name-style="western"><surname>Kay</surname><given-names>TW</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20111187</pub-id><pub-id pub-id-type="pmid">22213807</pub-id><pub-id pub-id-type="pmcid">PMC3260877</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>M</given-names></name><name name-style="western"><surname>Powers</surname><given-names>AC</given-names></name><name name-style="western"><surname>Clare-Salzler</surname><given-names>M</given-names></name></person-group><article-title>Current concepts on the pathogenesis of type 1 diabetes &#8211; considerations for attempts to prevent and reverse the disease</article-title>. <source>Diabetes Care</source> (<year>2015</year>) <volume>38</volume>(<issue>6</issue>):<fpage>979</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.2337/dc15-0144</pub-id><pub-id pub-id-type="pmid">25998290</pub-id><pub-id pub-id-type="pmcid">PMC4439528</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>VB</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V</given-names></name><name name-style="western"><surname>Bingley</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Todd</surname><given-names>JA</given-names></name><name name-style="western"><surname>Guy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Beta-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with type 1 diabetes compared with adults</article-title>. <source>Diabet Med</source> (<year>2017</year>) <volume>34</volume>(<issue>3</issue>):<fpage>419</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1111/dme.13153</pub-id><pub-id pub-id-type="pmid">27151105</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heninger</surname><given-names>AK</given-names></name><name name-style="western"><surname>Eugster</surname><given-names>A</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>D</given-names></name><name name-style="western"><surname>Buettner</surname><given-names>F</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>A</given-names></name><etal/></person-group><article-title>A divergent population of autoantigen-responsive CD4+ T cells in infants prior to beta cell autoimmunity</article-title>. <source>Sci Transl Med</source> (<year>2017</year>) <volume>9</volume>(<issue>378</issue>):<fpage>eaaf8848</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf8848</pub-id><pub-id pub-id-type="pmid">28228602</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Willcox</surname><given-names>A</given-names></name><name name-style="western"><surname>Bone</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>NG</given-names></name><name name-style="western"><surname>Foulis</surname><given-names>AK</given-names></name></person-group>. <article-title>Immunopathology of the human pancreas in type-I diabetes</article-title>. <source>Semin Immunopathol</source> (<year>2011</year>) <volume>33</volume>(<issue>1</issue>):<fpage>9</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1007/s00281-010-0205-0</pub-id><pub-id pub-id-type="pmid">20424842</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coppieters</surname><given-names>KT</given-names></name><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>MG</given-names></name></person-group><article-title>Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology</article-title>. <source>Semin Immunopathol</source> (<year>2011</year>) <volume>33</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/s00281-010-0236-6</pub-id><pub-id pub-id-type="pmid">21170533</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></name><name name-style="western"><surname>Fu</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaddis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>C</given-names></name><name name-style="western"><surname>Schatz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></name><etal/></person-group><article-title>Insulitis and beta-cell mass in the natural history of type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2016</year>) <volume>65</volume>(<issue>3</issue>):<fpage>719</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.2337/db15-0779</pub-id><pub-id pub-id-type="pmid">26581594</pub-id><pub-id pub-id-type="pmcid">PMC4764143</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></name></person-group>. <article-title>Organ donor specimens: what can they tell us about type 1 diabetes?</article-title><source>Pediatr Diabetes</source> (<year>2015</year>) <volume>16</volume>(<issue>5</issue>):<fpage>320</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1111/pedi.12286</pub-id><pub-id pub-id-type="pmid">25998576</pub-id><pub-id pub-id-type="pmcid">PMC4718555</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>In&#8217;t Veld</surname><given-names>P</given-names></name></person-group>. <article-title>Insulitis in human type 1 diabetes: the quest for an elusive lesion</article-title>. <source>Islets</source> (<year>2011</year>) <volume>3</volume>(<issue>4</issue>):<fpage>131</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4161/isl.3.4.15728</pub-id><pub-id pub-id-type="pmid">21606672</pub-id><pub-id pub-id-type="pmcid">PMC3154446</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skog</surname><given-names>O</given-names></name><name name-style="western"><surname>Korsgren</surname><given-names>S</given-names></name><name name-style="western"><surname>Melhus</surname><given-names>A</given-names></name><name name-style="western"><surname>Korsgren</surname><given-names>O</given-names></name></person-group>. <article-title>Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source> (<year>2013</year>) <volume>20</volume>(<issue>2</issue>):<fpage>118</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1097/MED.0b013e32835edb89</pub-id><pub-id pub-id-type="pmid">23422243</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gianani</surname><given-names>R</given-names></name></person-group>. <article-title>The pancreas in human type 1 diabetes: providing new answers to age-old questions</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source> (<year>2009</year>) <volume>16</volume>(<issue>4</issue>):<fpage>279</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1097/MED.0b013e32832e06ba</pub-id><pub-id pub-id-type="pmid">19502978</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>SC</given-names></name><name name-style="western"><surname>Mannering</surname><given-names>SI</given-names></name><name name-style="western"><surname>Michels</surname><given-names>AW</given-names></name><name name-style="western"><surname>Babon</surname><given-names>JAB</given-names></name></person-group><article-title>Deciphering the pathogenesis of human type 1 diabetes (T1D) by interrogating T cells from the &#8220;scene of the crime&#8221;</article-title>. <source>Curr Diab Rep</source> (<year>2017</year>) <volume>17</volume>(<issue>10</issue>):<fpage>95</fpage><pub-id pub-id-type="doi">10.1007/s11892-017-0915-y</pub-id><pub-id pub-id-type="pmid">28864875</pub-id><pub-id pub-id-type="pmcid">PMC5600889</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Tourino</surname><given-names>I</given-names></name><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Eichmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name></person-group>. <article-title>T cells in type 1 diabetes: instructors, regulators and effectors: a comprehensive review</article-title>. <source>J Autoimmun</source> (<year>2016</year>) <volume>66</volume>:<fpage>7</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2015.08.012</pub-id><pub-id pub-id-type="pmid">26343335</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Tree</surname><given-names>TI</given-names></name><name name-style="western"><surname>Astill</surname><given-names>TP</given-names></name><name name-style="western"><surname>Tremble</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health</article-title>. <source>J Clin Invest</source> (<year>2004</year>) <volume>113</volume>(<issue>3</issue>):<fpage>451</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1172/JCI19585</pub-id><pub-id pub-id-type="pmid">14755342</pub-id><pub-id pub-id-type="pmcid">PMC324541</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>LS</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>M</given-names></name></person-group>. <article-title>CD4 T cell differentiation in type 1 diabetes</article-title>. <source>Clin Exp Immunol</source> (<year>2016</year>) <volume>183</volume>(<issue>1</issue>):<fpage>16</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1111/cei.12672</pub-id><pub-id pub-id-type="pmid">26102289</pub-id><pub-id pub-id-type="pmcid">PMC4687517</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emamaullee</surname><given-names>JA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J</given-names></name><name name-style="western"><surname>Merani</surname><given-names>S</given-names></name><name name-style="western"><surname>Toso</surname><given-names>C</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>JF</given-names></name><name name-style="western"><surname>Thiesen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inhibition of Th17&#8201;cells regulates autoimmune diabetes in NOD mice</article-title>. <source>Diabetes</source> (<year>2009</year>) <volume>58</volume>(<issue>6</issue>):<fpage>1302</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.2337/db08-1113</pub-id><pub-id pub-id-type="pmid">19289457</pub-id><pub-id pub-id-type="pmcid">PMC2682686</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marwaha</surname><given-names>AK</given-names></name><name name-style="western"><surname>Crome</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Panagiotopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Berg</surname><given-names>KB</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>(<issue>7</issue>):<fpage>3814</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1001860</pub-id><pub-id pub-id-type="pmid">20810982</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraro</surname><given-names>A</given-names></name><name name-style="western"><surname>Socci</surname><given-names>C</given-names></name><name name-style="western"><surname>Stabilini</surname><given-names>A</given-names></name><name name-style="western"><surname>Valle</surname><given-names>A</given-names></name><name name-style="western"><surname>Monti</surname><given-names>P</given-names></name><name name-style="western"><surname>Piemonti</surname><given-names>L</given-names></name><etal/></person-group><article-title>Expansion of Th17&#8201;cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2011</year>) <volume>60</volume>(<issue>11</issue>):<fpage>2903</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.2337/db11-0090</pub-id><pub-id pub-id-type="pmid">21896932</pub-id><pub-id pub-id-type="pmcid">PMC3198077</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Rieck</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanda</surname><given-names>S</given-names></name><name name-style="western"><surname>Pihoker</surname><given-names>C</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></name></person-group>. <article-title>The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>10</issue>):<fpage>7350</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.10.7350</pub-id><pub-id pub-id-type="pmid">18981158</pub-id><pub-id pub-id-type="pmcid">PMC2597079</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Alise</surname><given-names>AM</given-names></name><name name-style="western"><surname>Auyeung</surname><given-names>V</given-names></name><name name-style="western"><surname>Feuerer</surname><given-names>M</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>J</given-names></name><name name-style="western"><surname>Fontenot</surname><given-names>J</given-names></name><name name-style="western"><surname>Benoist</surname><given-names>C</given-names></name><etal/></person-group><article-title>The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2008</year>) <volume>105</volume>(<issue>50</issue>):<fpage>19857</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0810713105</pub-id><pub-id pub-id-type="pmid">19073938</pub-id><pub-id pub-id-type="pmcid">PMC2604930</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hulme</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>CH</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Brusko</surname><given-names>TM</given-names></name></person-group>. <article-title>Central role for interleukin-2 in type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>1</issue>):<fpage>14</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.2337/db11-1213</pub-id><pub-id pub-id-type="pmid">22187370</pub-id><pub-id pub-id-type="pmcid">PMC3237657</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>G</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>JR</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Downes</surname><given-names>K</given-names></name><name name-style="western"><surname>Pekalski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>(<issue>9</issue>):<fpage>4644</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1100272</pub-id><pub-id pub-id-type="pmid">22461703</pub-id><pub-id pub-id-type="pmcid">PMC3378653</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brusko</surname><given-names>TM</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>CH</given-names></name><name name-style="western"><surname>Clare-Salzler</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schatz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name></person-group>. <article-title>Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2005</year>) <volume>54</volume>(<issue>5</issue>):<fpage>1407</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.54.5.1407</pub-id><pub-id pub-id-type="pmid">15855327</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindley</surname><given-names>S</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>A</given-names></name><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name><name name-style="western"><surname>Tree</surname><given-names>TI</given-names></name></person-group>. <article-title>Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2005</year>) <volume>54</volume>(<issue>1</issue>):<fpage>92</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.54.1.92</pub-id><pub-id pub-id-type="pmid">15616015</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Adams</surname><given-names>JY</given-names></name><name name-style="western"><surname>Penaranda</surname><given-names>C</given-names></name><name name-style="western"><surname>Melli</surname><given-names>K</given-names></name><name name-style="western"><surname>Piaggio</surname><given-names>E</given-names></name><name name-style="western"><surname>Sgouroudis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>28</volume>(<issue>5</issue>):<fpage>687</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.016</pub-id><pub-id pub-id-type="pmid">18468463</pub-id><pub-id pub-id-type="pmcid">PMC2394854</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>CM</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name><name name-style="western"><surname>Tree</surname><given-names>TIM</given-names></name></person-group>. <article-title>Regulatory T cell dysfunction in type 1 diabetes: what&#8217;s broken and how can we fix it?</article-title><source>Diabetologia</source> (<year>2017</year>) <volume>60</volume>(<issue>10</issue>):<fpage>1839</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-017-4377-1</pub-id><pub-id pub-id-type="pmid">28770318</pub-id><pub-id pub-id-type="pmcid">PMC6448885</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyara</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group>. <article-title>Natural regulatory T cells: mechanisms of suppression</article-title>. <source>Trends Mol Med</source> (<year>2007</year>) <volume>13</volume>(<issue>3</issue>):<fpage>108</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmed.2007.01.003</pub-id><pub-id pub-id-type="pmid">17257897</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goudy</surname><given-names>KS</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Garland</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>(<issue>6</issue>):<fpage>3779</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1001422</pub-id><pub-id pub-id-type="pmid">21317396</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Garland</surname><given-names>AL</given-names></name><name name-style="western"><surname>Nicolson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice</article-title>. <source>Diabetes</source> (<year>2013</year>) <volume>62</volume>(<issue>11</issue>):<fpage>3775</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.2337/db13-0669</pub-id><pub-id pub-id-type="pmid">23884888</pub-id><pub-id pub-id-type="pmcid">PMC3806588</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores</surname><given-names>RR</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>PD</given-names></name></person-group><article-title>Expression of IL-2 in beta cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells</article-title>. <source>Gene Ther</source> (<year>2014</year>) <volume>21</volume>(<issue>8</issue>):<fpage>715</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1038/gt.2014.45</pub-id><pub-id pub-id-type="pmid">24849041</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cerosaletti</surname><given-names>K</given-names></name><name name-style="western"><surname>Bollyky</surname><given-names>PL</given-names></name><name name-style="western"><surname>Tatum</surname><given-names>M</given-names></name><name name-style="western"><surname>Shilling</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects</article-title>. <source>Diabetes</source> (<year>2010</year>) <volume>59</volume>(<issue>2</issue>):<fpage>407</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.2337/db09-0694</pub-id><pub-id pub-id-type="pmid">19875613</pub-id><pub-id pub-id-type="pmcid">PMC2809970</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attridge</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wardzinski</surname><given-names>L</given-names></name><name name-style="western"><surname>Kenefeck</surname><given-names>R</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>JL</given-names></name><name name-style="western"><surname>Manzotti</surname><given-names>C</given-names></name><etal/></person-group><article-title>IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>(<issue>20</issue>):<fpage>4656</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-10-388546</pub-id><pub-id pub-id-type="pmid">22442347</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Leete</surname><given-names>P</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V</given-names></name><name name-style="western"><surname>Marks</surname><given-names>K</given-names></name><name name-style="western"><surname>Nor</surname><given-names>NM</given-names></name><name name-style="western"><surname>Estorninho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2014</year>) <volume>63</volume>(<issue>11</issue>):<fpage>3835</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.2337/db14-0365</pub-id><pub-id pub-id-type="pmid">24939426</pub-id><pub-id pub-id-type="pmcid">PMC4207393</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanda</surname><given-names>S</given-names></name><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>M</given-names></name></person-group>. <article-title>Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes</article-title>. <source>Clin Immunol</source> (<year>2008</year>) <volume>127</volume>(<issue>2</issue>):<fpage>138</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2007.12.003</pub-id><pub-id pub-id-type="pmid">18304876</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrich de Marquesini</surname><given-names>LG</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Connor</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McLintock</surname><given-names>NE</given-names></name><name name-style="western"><surname>Pope</surname><given-names>C</given-names></name><etal/></person-group><article-title>IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes</article-title>. <source>Diabetologia</source> (<year>2010</year>) <volume>53</volume>(<issue>7</issue>):<fpage>1451</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-010-1739-3</pub-id><pub-id pub-id-type="pmid">20369219</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Podolsky</surname><given-names>R</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>D</given-names></name><name name-style="western"><surname>Makala</surname><given-names>LH</given-names></name><name name-style="western"><surname>Muir</surname><given-names>A</given-names></name><etal/></person-group><article-title>APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes</article-title>. <source>Clin Immunol</source> (<year>2009</year>) <volume>130</volume>(<issue>3</issue>):<fpage>272</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2008.10.005</pub-id><pub-id pub-id-type="pmid">19036642</pub-id><pub-id pub-id-type="pmcid">PMC2671725</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serreze</surname><given-names>DV</given-names></name><name name-style="western"><surname>Gaskins</surname><given-names>HR</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>EH</given-names></name></person-group>. <article-title>Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice</article-title>. <source>J Immunol</source> (<year>1993</year>) <volume>150</volume>(<issue>6</issue>):<fpage>2534</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">8450229</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Ondr</surname><given-names>JK</given-names></name><name name-style="western"><surname>Opoka</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>EM</given-names></name></person-group>. <article-title>Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>(<issue>4</issue>):<fpage>1999</fpage>&#8211;<lpage>2003</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1001398</pub-id><pub-id pub-id-type="pmid">20644171</pub-id><pub-id pub-id-type="pmcid">PMC2916973</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poligone</surname><given-names>B</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Sen</surname><given-names>P</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>AS</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group>. <article-title>Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>168</volume>(<issue>1</issue>):<fpage>188</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.168.1.188</pub-id><pub-id pub-id-type="pmid">11751962</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Beller</surname><given-names>DI</given-names></name></person-group>. <article-title>Distinct pathways for NF-kappa B regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>170</volume>(<issue>9</issue>):<fpage>4489</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.170.9.4489</pub-id><pub-id pub-id-type="pmid">12707325</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uno</surname><given-names>S</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Okita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sayama</surname><given-names>K</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes</article-title>. <source>Diabetologia</source> (<year>2007</year>) <volume>50</volume>(<issue>3</issue>):<fpage>596</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-006-0569-9</pub-id><pub-id pub-id-type="pmid">17221211</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serreze</surname><given-names>DV</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>HD</given-names></name><name name-style="western"><surname>Varnum</surname><given-names>DS</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Reifsnyder</surname><given-names>PC</given-names></name><name name-style="western"><surname>Richard</surname><given-names>SD</given-names></name><etal/></person-group><article-title>B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new &#8220;speed congenic&#8221; stock of NOD.Ig mu null mice</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>184</volume>(<issue>5</issue>):<fpage>2049</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1084/jem.184.5.2049</pub-id><pub-id pub-id-type="pmid">8920894</pub-id><pub-id pub-id-type="pmcid">PMC2192892</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noorchashm</surname><given-names>H</given-names></name><name name-style="western"><surname>Noorchashm</surname><given-names>N</given-names></name><name name-style="western"><surname>Kern</surname><given-names>J</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>SY</given-names></name><name name-style="western"><surname>Barker</surname><given-names>CF</given-names></name><name name-style="western"><surname>Naji</surname><given-names>A</given-names></name></person-group>. <article-title>B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice</article-title>. <source>Diabetes</source> (<year>1997</year>) <volume>46</volume>(<issue>6</issue>):<fpage>941</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.46.6.941</pub-id><pub-id pub-id-type="pmid">9166663</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>E</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>PA</given-names></name><name name-style="western"><surname>Stolp</surname><given-names>J</given-names></name><name name-style="western"><surname>Grey</surname><given-names>ST</given-names></name></person-group>. <article-title>B cell-directed therapies in type 1 diabetes</article-title>. <source>Trends Immunol</source> (<year>2011</year>) <volume>32</volume>(<issue>6</issue>):<fpage>287</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2011.03.006</pub-id><pub-id pub-id-type="pmid">21531625</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cnop</surname><given-names>M</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>N</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jorns</surname><given-names>A</given-names></name><name name-style="western"><surname>Lenzen</surname><given-names>S</given-names></name><name name-style="western"><surname>Eizirik</surname><given-names>DL</given-names></name></person-group>. <article-title>Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities</article-title>. <source>Diabetes</source> (<year>2005</year>) <volume>54</volume>(<issue>Suppl 2</issue>):<fpage>S97</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.54.suppl_2.S97</pub-id><pub-id pub-id-type="pmid">16306347</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>KM</given-names></name><name name-style="western"><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Type 1 diabetes: a predictable disease</article-title>. <source>World J Diabetes</source> (<year>2015</year>) <volume>6</volume>(<issue>3</issue>):<fpage>380</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.4239/wjd.v6.i3.380</pub-id><pub-id pub-id-type="pmid">25897349</pub-id><pub-id pub-id-type="pmcid">PMC4398895</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regnell</surname><given-names>SE</given-names></name><name name-style="western"><surname>Lernmark</surname><given-names>A</given-names></name></person-group>. <article-title>Early prediction of autoimmune (type 1) diabetes</article-title>. <source>Diabetologia</source> (<year>2017</year>) <volume>60</volume>(<issue>8</issue>):<fpage>1370</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-017-4308-1</pub-id><pub-id pub-id-type="pmid">28550517</pub-id><pub-id pub-id-type="pmcid">PMC5491594</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>AG</given-names></name><name name-style="western"><surname>Rewers</surname><given-names>M</given-names></name><name name-style="western"><surname>Simell</surname><given-names>O</given-names></name><name name-style="western"><surname>Simell</surname><given-names>T</given-names></name><name name-style="western"><surname>Lempainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Steck</surname><given-names>A</given-names></name><etal/></person-group><article-title>Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children</article-title>. <source>JAMA</source> (<year>2013</year>) <volume>309</volume>(<issue>23</issue>):<fpage>2473</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1001/jama.2013.6285</pub-id><pub-id pub-id-type="pmid">23780460</pub-id><pub-id pub-id-type="pmcid">PMC4878912</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Cohrs</surname><given-names>CM</given-names></name><name name-style="western"><surname>Stertmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Bozsak</surname><given-names>R</given-names></name><name name-style="western"><surname>Speier</surname><given-names>S</given-names></name></person-group>. <article-title>Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis</article-title>. <source>Mol Metab</source> (<year>2017</year>) <volume>6</volume>(<issue>9</issue>):<fpage>943</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmet.2017.06.019</pub-id><pub-id pub-id-type="pmid">28951820</pub-id><pub-id pub-id-type="pmcid">PMC5605733</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>BM</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Oram</surname><given-names>R</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>M</given-names></name><name name-style="western"><surname>Leete</surname><given-names>P</given-names></name><etal/></person-group><article-title>C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase</article-title>. <source>Diabetes Care</source> (<year>2018</year>) <volume>41</volume>(<issue>7</issue>):<fpage>1486</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.2337/dc18-0465</pub-id><pub-id pub-id-type="pmid">29880650</pub-id><pub-id pub-id-type="pmcid">PMC6027962</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougneres</surname><given-names>PF</given-names></name><name name-style="western"><surname>Landais</surname><given-names>P</given-names></name><name name-style="western"><surname>Boisson</surname><given-names>C</given-names></name><name name-style="western"><surname>Carel</surname><given-names>JC</given-names></name><name name-style="western"><surname>Frament</surname><given-names>N</given-names></name><name name-style="western"><surname>Boitard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin</article-title>. <source>Diabetes</source> (<year>1990</year>) <volume>39</volume>(<issue>10</issue>):<fpage>1264</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.2337/diab.39.10.1264</pub-id><pub-id pub-id-type="pmid">2210078</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stiller</surname><given-names>CR</given-names></name><name name-style="western"><surname>Dupre</surname><given-names>J</given-names></name><name name-style="western"><surname>Gent</surname><given-names>M</given-names></name><name name-style="western"><surname>Jenner</surname><given-names>MR</given-names></name><name name-style="western"><surname>Keown</surname><given-names>PA</given-names></name><name name-style="western"><surname>Laupacis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset</article-title>. <source>Science</source> (<year>1984</year>) <volume>223</volume>(<issue>4643</issue>):<fpage>1362</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1126/science.6367043</pub-id><pub-id pub-id-type="pmid">6367043</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Hagopian</surname><given-names>W</given-names></name><name name-style="western"><surname>Auger</surname><given-names>JA</given-names></name><name name-style="western"><surname>Poumian-Ruiz</surname><given-names>E</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus</article-title>. <source>N Engl J Med</source> (<year>2002</year>) <volume>346</volume>(<issue>22</issue>):<fpage>1692</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa012864</pub-id><pub-id pub-id-type="pmid">12037148</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoda</surname><given-names>LK</given-names></name><name name-style="western"><surname>Young</surname><given-names>DL</given-names></name><name name-style="western"><surname>Ramanujan</surname><given-names>S</given-names></name><name name-style="western"><surname>Whiting</surname><given-names>CC</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><etal/></person-group><article-title>A comprehensive review of interventions in the NOD mouse and implications for translation</article-title>. <source>Immunity</source> (<year>2005</year>) <volume>23</volume>(<issue>2</issue>):<fpage>115</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2005.08.002</pub-id><pub-id pub-id-type="pmid">16111631</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perruche</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saas</surname><given-names>P</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group>. <article-title>CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells</article-title>. <source>Nat Med</source> (<year>2008</year>) <volume>14</volume>(<issue>5</issue>):<fpage>528</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1038/nm1749</pub-id><pub-id pub-id-type="pmid">18438416</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name></person-group>. <article-title>CD3-specific antibodies: a portal to the treatment of autoimmunity</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>8</issue>):<fpage>622</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1038/nri2134</pub-id><pub-id pub-id-type="pmid">17641665</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belghith</surname><given-names>M</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Barriot</surname><given-names>S</given-names></name><name name-style="western"><surname>Megret</surname><given-names>J</given-names></name><name name-style="western"><surname>Bach</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name></person-group>. <article-title>TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes</article-title>. <source>Nat Med</source> (<year>2003</year>) <volume>9</volume>(<issue>9</issue>):<fpage>1202</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nm924</pub-id><pub-id pub-id-type="pmid">12937416</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Recino</surname><given-names>A</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>J</given-names></name><name name-style="western"><surname>Howie</surname><given-names>D</given-names></name><name name-style="western"><surname>Vienne</surname><given-names>M</given-names></name><name name-style="western"><surname>Paluch</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity</article-title>. <source>Immunology</source> (<year>2017</year>) <volume>151</volume>(<issue>2</issue>):<fpage>248</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1111/imm.12729</pub-id><pub-id pub-id-type="pmid">28211040</pub-id><pub-id pub-id-type="pmcid">PMC5418468</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name><name name-style="western"><surname>Primo</surname><given-names>J</given-names></name><name name-style="western"><surname>Bach</surname><given-names>JF</given-names></name></person-group>. <article-title>CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>158</volume>(<issue>6</issue>):<fpage>2947</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">9058834</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keymeulen</surname><given-names>B</given-names></name><name name-style="western"><surname>Vandemeulebroucke</surname><given-names>E</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>AG</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>L</given-names></name><name name-style="western"><surname>Hale</surname><given-names>G</given-names></name><etal/></person-group><article-title>Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes</article-title>. <source>N Engl J Med</source> (<year>2005</year>) <volume>352</volume>(<issue>25</issue>):<fpage>2598</fpage>&#8211;<lpage>608</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa043980</pub-id><pub-id pub-id-type="pmid">15972866</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>S</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Puck</surname><given-names>J</given-names></name><name name-style="western"><surname>Hagopian</surname><given-names>W</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years</article-title>. <source>Clin Immunol</source> (<year>2009</year>) <volume>132</volume>(<issue>2</issue>):<fpage>166</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2009.04.007</pub-id><pub-id pub-id-type="pmid">19443276</pub-id><pub-id pub-id-type="pmcid">PMC2735402</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ehlers</surname><given-names>MR</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Hagopian</surname><given-names>W</given-names></name><etal/></person-group><article-title>Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders</article-title>. <source>Diabetes</source> (<year>2013</year>) <volume>62</volume>(<issue>11</issue>):<fpage>3766</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.2337/db13-0345</pub-id><pub-id pub-id-type="pmid">23835333</pub-id><pub-id pub-id-type="pmcid">PMC3806618</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Masharani</surname><given-names>U</given-names></name><name name-style="western"><surname>Hagopian</surname><given-names>W</given-names></name><name name-style="western"><surname>Bisikirska</surname><given-names>B</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>D</given-names></name><etal/></person-group><article-title>A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2005</year>) <volume>54</volume>(<issue>6</issue>):<fpage>1763</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.54.6.1763</pub-id><pub-id pub-id-type="pmid">15919798</pub-id><pub-id pub-id-type="pmcid">PMC5315015</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Willi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Waldron-Lynch</surname><given-names>F</given-names></name><name name-style="western"><surname>Devine</surname><given-names>L</given-names></name><etal/></person-group><article-title>Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial</article-title>. <source>Diabetologia</source> (<year>2013</year>) <volume>56</volume>(<issue>2</issue>):<fpage>391</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-012-2753-4</pub-id><pub-id pub-id-type="pmid">23086558</pub-id><pub-id pub-id-type="pmcid">PMC3537871</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>J</given-names></name><name name-style="western"><surname>DeBerg</surname><given-names>HA</given-names></name><name name-style="western"><surname>Gersuk</surname><given-names>V</given-names></name><name name-style="western"><surname>Eddy</surname><given-names>J</given-names></name><name name-style="western"><surname>Harris</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes</article-title>. <source>Sci Immunol</source> (<year>2016</year>) <volume>1</volume>(<issue>5</issue>):<fpage>eaai7793</fpage>.<pub-id pub-id-type="doi">10.1126/sciimmunol.aai7793</pub-id><pub-id pub-id-type="pmid">28664195</pub-id><pub-id pub-id-type="pmcid">PMC5486405</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>J</given-names></name><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><name name-style="western"><surname>Ehlers</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanda</surname><given-names>S</given-names></name><name name-style="western"><surname>Lim</surname><given-names>N</given-names></name><etal/></person-group><article-title>Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes</article-title>. <source>Cell Immunol</source> (<year>2017</year>) <volume>319</volume>:<fpage>3</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.cellimm.2017.07.007</pub-id><pub-id pub-id-type="pmid">28844471</pub-id><pub-id pub-id-type="pmcid">PMC5614459</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tooley</surname><given-names>JE</given-names></name><name name-style="western"><surname>Vudattu</surname><given-names>N</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cotsapas</surname><given-names>C</given-names></name><name name-style="western"><surname>Devine</surname><given-names>L</given-names></name><name name-style="western"><surname>Raddassi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes</article-title>. <source>Eur J Immunol</source> (<year>2016</year>) <volume>46</volume>(<issue>1</issue>):<fpage>230</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201545708</pub-id><pub-id pub-id-type="pmid">26518356</pub-id><pub-id pub-id-type="pmcid">PMC4882099</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vudattu</surname><given-names>NK</given-names></name><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name></person-group>. <article-title>Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development</article-title>. <source>Expert Opin Biol Ther</source> (<year>2014</year>) <volume>14</volume>(<issue>3</issue>):<fpage>377</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1517/14712598.2014.881797</pub-id><pub-id pub-id-type="pmid">24517093</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daifotis</surname><given-names>AG</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>S</given-names></name><name name-style="western"><surname>Chatenoud</surname><given-names>L</given-names></name><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name></person-group>. <article-title>Anti-CD3 clinical trials in type 1 diabetes mellitus</article-title>. <source>Clin Immunol</source> (<year>2013</year>) <volume>149</volume>(<issue>3</issue>):<fpage>268</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2013.05.001</pub-id><pub-id pub-id-type="pmid">23726024</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ablamunits</surname><given-names>V</given-names></name><name name-style="western"><surname>Henegariu</surname><given-names>O</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Opare-Addo</surname><given-names>L</given-names></name><name name-style="western"><surname>Preston-Hurlburt</surname><given-names>P</given-names></name><name name-style="western"><surname>Santamaria</surname><given-names>P</given-names></name><etal/></person-group><article-title>Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>1</issue>):<fpage>145</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.2337/db11-1033</pub-id><pub-id pub-id-type="pmid">22043003</pub-id><pub-id pub-id-type="pmcid">PMC3237664</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherry</surname><given-names>NA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>JA</given-names></name><name name-style="western"><surname>Glandt</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells</article-title>. <source>Endocrinology</source> (<year>2007</year>) <volume>148</volume>(<issue>11</issue>):<fpage>5136</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1210/en.2007-0358</pub-id><pub-id pub-id-type="pmid">17673522</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyslop</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>V</given-names></name><name name-style="western"><surname>Santamaria</surname><given-names>P</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name></person-group>. <article-title>Prolactin as an adjunct for type 1 diabetes immunotherapy</article-title>. <source>Endocrinology</source> (<year>2016</year>) <volume>157</volume>(<issue>1</issue>):<fpage>150</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1210/en.2015-1549</pub-id><pub-id pub-id-type="pmid">26512750</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>CH</given-names></name><name name-style="western"><surname>Campbell-Thompson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice</article-title>. <source>Diabetes</source> (<year>2009</year>) <volume>58</volume>(<issue>10</issue>):<fpage>2277</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.2337/db09-0557</pub-id><pub-id pub-id-type="pmid">19628781</pub-id><pub-id pub-id-type="pmcid">PMC2750219</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haller</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Michels</surname><given-names>AW</given-names></name><name name-style="western"><surname>Perry</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2016</year>) <volume>65</volume>(<issue>12</issue>):<fpage>3765</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.2337/db16-0823</pub-id><pub-id pub-id-type="pmid">27669730</pub-id><pub-id pub-id-type="pmcid">PMC5127248</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamad</surname><given-names>AR</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name><name name-style="western"><surname>Donner</surname><given-names>T</given-names></name><name name-style="western"><surname>Fousteri</surname><given-names>G</given-names></name></person-group>. <article-title>B cell-targeted immunotherapy for type 1 diabetes: what can make it work?</article-title><source>Discov Med</source> (<year>2016</year>) <volume>21</volume>(<issue>115</issue>):<fpage>213</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27115172</pub-id><pub-id pub-id-type="pmcid">PMC5266520</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musette</surname><given-names>P</given-names></name><name name-style="western"><surname>Bouaziz</surname><given-names>JD</given-names></name></person-group>. <article-title>B cell modulation strategies in autoimmune diseases: new concepts</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<fpage>622</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2018.00622</pub-id><pub-id pub-id-type="pmid">29706952</pub-id><pub-id pub-id-type="pmcid">PMC5908887</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Rodriguez-Pinto</surname><given-names>D</given-names></name><name name-style="western"><surname>Du</surname><given-names>W</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>A</given-names></name><name name-style="western"><surname>Henegariu</surname><given-names>O</given-names></name><name name-style="western"><surname>Wong</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice</article-title>. <source>J Clin Invest</source> (<year>2007</year>) <volume>117</volume>(<issue>12</issue>):<fpage>3857</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1172/JCI32405</pub-id><pub-id pub-id-type="pmid">18060033</pub-id><pub-id pub-id-type="pmcid">PMC2096456</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CP</given-names></name><name name-style="western"><surname>Bouaziz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Hamaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pop</surname><given-names>SM</given-names></name><etal/></person-group><article-title>B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>(<issue>5</issue>):<fpage>2863</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.180.5.2863</pub-id><pub-id pub-id-type="pmid">18292508</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorina</surname><given-names>P</given-names></name><name name-style="western"><surname>Vergani</surname><given-names>A</given-names></name><name name-style="western"><surname>Dada</surname><given-names>S</given-names></name><name name-style="western"><surname>Jurewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Law</surname><given-names>K</given-names></name><etal/></person-group><article-title>Targeting CD22 reprograms B-cells and reverses autoimmune diabetes</article-title>. <source>Diabetes</source> (<year>2008</year>) <volume>57</volume>(<issue>11</issue>):<fpage>3013</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.2337/db08-0420</pub-id><pub-id pub-id-type="pmid">18689692</pub-id><pub-id pub-id-type="pmcid">PMC2570398</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zekavat</surname><given-names>G</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>SY</given-names></name><name name-style="western"><surname>Badkerhanian</surname><given-names>A</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>RF</given-names></name><name name-style="western"><surname>Koeberlein</surname><given-names>B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><etal/></person-group><article-title>In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>11</issue>):<fpage>8133</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.11.8133</pub-id><pub-id pub-id-type="pmid">19018006</pub-id><pub-id pub-id-type="pmcid">PMC2586964</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>E</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>J</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Liuwantara</surname><given-names>D</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>F</given-names></name><name name-style="western"><surname>Grey</surname><given-names>ST</given-names></name></person-group>. <article-title>CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells</article-title>. <source>Diabetes</source> (<year>2009</year>) <volume>58</volume>(<issue>7</issue>):<fpage>1568</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.2337/db08-1504</pub-id><pub-id pub-id-type="pmid">19336675</pub-id><pub-id pub-id-type="pmcid">PMC2699852</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pescovitz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Krause-Steinrauf</surname><given-names>H</given-names></name><name name-style="western"><surname>Becker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rituximab, B-lymphocyte depletion, and preservation of beta-cell function</article-title>. <source>N Engl J Med</source> (<year>2009</year>) <volume>361</volume>(<issue>22</issue>):<fpage>2143</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa0904452</pub-id><pub-id pub-id-type="pmid">19940299</pub-id><pub-id pub-id-type="pmcid">PMC6410357</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>MD</given-names></name><name name-style="western"><surname>Keystone</surname><given-names>E</given-names></name></person-group>. <article-title>Rituximab for rheumatoid arthritis</article-title>. <source>Rheumatol Ther</source> (<year>2015</year>) <volume>2</volume>(<issue>2</issue>):<fpage>99</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="doi">10.1007/s40744-015-0016-9</pub-id><pub-id pub-id-type="pmid">27747531</pub-id><pub-id pub-id-type="pmcid">PMC4883263</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Diz</surname><given-names>R</given-names></name><name name-style="western"><surname>Martin</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Morillon</surname><given-names>YM</given-names></name><name name-style="western"><surname>Kline</surname><given-names>DE</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>11</issue>):<fpage>2871</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.2337/db12-0098</pub-id><pub-id pub-id-type="pmid">22751694</pub-id><pub-id pub-id-type="pmcid">PMC3478559</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>JM</given-names></name><name name-style="western"><surname>Parish</surname><given-names>NM</given-names></name><name name-style="western"><surname>Raine</surname><given-names>T</given-names></name><name name-style="western"><surname>Bland</surname><given-names>C</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>Y</given-names></name><name name-style="western"><surname>De La Pena</surname><given-names>H</given-names></name><etal/></person-group><article-title>Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations</article-title>. <source>Rev Diabet Stud</source> (<year>2009</year>) <volume>6</volume>(<issue>2</issue>):<fpage>97</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1900/RDS.2009.6.97</pub-id><pub-id pub-id-type="pmid">19806239</pub-id><pub-id pub-id-type="pmcid">PMC2779016</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchings</surname><given-names>P</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>L</given-names></name><name name-style="western"><surname>Parish</surname><given-names>NM</given-names></name><name name-style="western"><surname>Waldmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>A</given-names></name></person-group>. <article-title>The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice</article-title>. <source>Eur J Immunol</source> (<year>1992</year>) <volume>22</volume>(<issue>7</issue>):<fpage>1913</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830220735</pub-id><pub-id pub-id-type="pmid">1623929</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>JM</given-names></name><name name-style="western"><surname>Harach</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Parish</surname><given-names>NM</given-names></name><name name-style="western"><surname>Fehervari</surname><given-names>Z</given-names></name><name name-style="western"><surname>Haskins</surname><given-names>K</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>A</given-names></name></person-group>. <article-title>Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>165</volume>(<issue>4</issue>):<fpage>1949</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.165.4.1949</pub-id><pub-id pub-id-type="pmid">10925277</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pullar</surname><given-names>CE</given-names></name><name name-style="western"><surname>Morris</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wood</surname><given-names>KJ</given-names></name></person-group>. <article-title>Altered proximal T-cell receptor signalling events in mouse CD4+ T cells in the presence of anti-CD4 monoclonal antibodies: evidence for reduced phosphorylation of Zap-70 and LAT</article-title>. <source>Scand J Immunol</source> (<year>2003</year>) <volume>57</volume>(<issue>4</issue>):<fpage>333</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-3083.2003.01241.x</pub-id><pub-id pub-id-type="pmid">12662296</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M</given-names></name><name name-style="western"><surname>Gojanovich</surname><given-names>G</given-names></name><name name-style="western"><surname>Manzoor</surname><given-names>F</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K</given-names></name><name name-style="western"><surname>Kline</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues</article-title>. <source>JCI Insight</source> (<year>2016</year>) <volume>1</volume>(<issue>17</issue>):<fpage>e87636</fpage>.<pub-id pub-id-type="doi">10.1172/jci.insight.87636</pub-id><pub-id pub-id-type="pmid">27777971</pub-id><pub-id pub-id-type="pmcid">PMC5070954</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orban</surname><given-names>T</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>DiMeglio</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source> (<year>2011</year>) <volume>378</volume>(<issue>9789</issue>):<fpage>412</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60886-6</pub-id><pub-id pub-id-type="pmid">21719096</pub-id><pub-id pub-id-type="pmcid">PMC3462593</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orban</surname><given-names>T</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Dimeglio</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment</article-title>. <source>Diabetes Care</source> (<year>2014</year>) <volume>37</volume>(<issue>4</issue>):<fpage>1069</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.2337/dc13-0604</pub-id><pub-id pub-id-type="pmid">24296850</pub-id><pub-id pub-id-type="pmcid">PMC3964491</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>N</given-names></name><name name-style="western"><surname>Imagawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Hanafusa</surname><given-names>T</given-names></name><name name-style="western"><surname>Waguri</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwahashi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice</article-title>. <source>J Exp Med</source> (<year>1997</year>) <volume>186</volume>(<issue>4</issue>):<fpage>613</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1084/jem.186.4.613</pub-id><pub-id pub-id-type="pmid">9254659</pub-id><pub-id pub-id-type="pmcid">PMC2199040</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chervonsky</surname><given-names>AV</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wong</surname><given-names>FS</given-names></name><name name-style="western"><surname>Visintin</surname><given-names>I</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>RA</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>The role of Fas in autoimmune diabetes</article-title>. <source>Cell</source> (<year>1997</year>) <volume>89</volume>(<issue>1</issue>):<fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80178-6</pub-id><pub-id pub-id-type="pmid">9094710</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mohamood</surname><given-names>AS</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>S</given-names></name><name name-style="western"><surname>Gutfreund</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>C</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development</article-title>. <source>Am J Pathol</source> (<year>2011</year>) <volume>179</volume>(<issue>2</issue>):<fpage>725</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/j.ajpath.2011.04.016</pub-id><pub-id pub-id-type="pmid">21718680</pub-id><pub-id pub-id-type="pmcid">PMC3157218</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalden</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schulze-Koops</surname><given-names>H</given-names></name></person-group>. <article-title>Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment</article-title>. <source>Nat Rev Rheumatol</source> (<year>2017</year>) <volume>13</volume>(<issue>12</issue>):<fpage>707</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1038/nrrheum.2017.187</pub-id><pub-id pub-id-type="pmid">29158574</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>XD</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name><name name-style="western"><surname>Singer</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cao</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Liblau</surname><given-names>RS</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process</article-title>. <source>J Exp Med</source> (<year>1994</year>) <volume>180</volume>(<issue>3</issue>):<fpage>995</fpage>&#8211;<lpage>1004</lpage>.<pub-id pub-id-type="doi">10.1084/jem.180.3.995</pub-id><pub-id pub-id-type="pmid">8064245</pub-id><pub-id pub-id-type="pmcid">PMC2191653</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chee</surname><given-names>J</given-names></name><name name-style="western"><surname>Angstetra</surname><given-names>E</given-names></name><name name-style="western"><surname>Mariana</surname><given-names>L</given-names></name><name name-style="western"><surname>Graham</surname><given-names>KL</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>EM</given-names></name><name name-style="western"><surname>Bluethmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>TNF receptor 1 deficiency increases regulatory T cell function in nonobese diabetic mice</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>(<issue>4</issue>):<fpage>1702</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1100511</pub-id><pub-id pub-id-type="pmid">21734073</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastrandrea</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>T</given-names></name><name name-style="western"><surname>Buchlis</surname><given-names>J</given-names></name><name name-style="western"><surname>Albini</surname><given-names>C</given-names></name><name name-style="western"><surname>Fourtner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study</article-title>. <source>Diabetes Care</source> (<year>2009</year>) <volume>32</volume>(<issue>7</issue>):<fpage>1244</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.2337/dc09-0054</pub-id><pub-id pub-id-type="pmid">19366957</pub-id><pub-id pub-id-type="pmcid">PMC2699714</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timper</surname><given-names>K</given-names></name><name name-style="western"><surname>Hruz</surname><given-names>P</given-names></name><name name-style="western"><surname>Beglinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Donath</surname><given-names>MY</given-names></name></person-group><article-title>Infliximab in the treatment of Crohn disease and type 1 diabetes</article-title>. <source>Diabetes Care</source> (<year>2013</year>) <volume>36</volume>(<issue>7</issue>):<fpage>e90</fpage>&#8211;<lpage>1</lpage>.<pub-id pub-id-type="doi">10.2337/dc13-0199</pub-id><pub-id pub-id-type="pmid">23801815</pub-id><pub-id pub-id-type="pmcid">PMC3687309</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tack</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kleijwegt</surname><given-names>FS</given-names></name><name name-style="western"><surname>Van Riel</surname><given-names>PL</given-names></name><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name></person-group><article-title>Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis</article-title>. <source>Diabetologia</source> (<year>2009</year>) <volume>52</volume>(<issue>7</issue>):<fpage>1442</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-009-1381-0</pub-id><pub-id pub-id-type="pmid">19440690</pub-id><pub-id pub-id-type="pmcid">PMC2688610</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cox</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kahan</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>JT</given-names></name><name name-style="western"><surname>Bakshi</surname><given-names>RK</given-names></name><name name-style="western"><surname>Zajac</surname><given-names>AJ</given-names></name></person-group>. <article-title>A context-dependent role for IL-21 in modulating the differentiation, distribution, and abundance of effector and memory CD8 T cell subsets</article-title>. <source>J Immunol</source> (<year>2016</year>) <volume>196</volume>(<issue>5</issue>):<fpage>2153</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1401236</pub-id><pub-id pub-id-type="pmid">26826252</pub-id><pub-id pub-id-type="pmcid">PMC4761492</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zajac</surname><given-names>AJ</given-names></name></person-group>. <article-title>IL-21 and T cell differentiation: consider the context</article-title>. <source>Trends Immunol</source> (<year>2016</year>) <volume>37</volume>(<issue>8</issue>):<fpage>557</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2016.06.001</pub-id><pub-id pub-id-type="pmid">27389961</pub-id><pub-id pub-id-type="pmcid">PMC4969098</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beringer</surname><given-names>A</given-names></name><name name-style="western"><surname>Noack</surname><given-names>M</given-names></name><name name-style="western"><surname>Miossec</surname><given-names>P</given-names></name></person-group>. <article-title>IL-17 in chronic inflammation: from discovery to targeting</article-title>. <source>Trends Mol Med</source> (<year>2016</year>) <volume>22</volume>(<issue>3</issue>):<fpage>230</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmed.2016.01.001</pub-id><pub-id pub-id-type="pmid">26837266</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurer</surname><given-names>MF</given-names></name><name name-style="western"><surname>Garrigues</surname><given-names>U</given-names></name><name name-style="western"><surname>Jaspers</surname><given-names>SR</given-names></name><name name-style="western"><surname>Meengs</surname><given-names>B</given-names></name><name name-style="western"><surname>Rixon</surname><given-names>MW</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies</article-title>. <source>MAbs</source> (<year>2012</year>) <volume>4</volume>(<issue>1</issue>):<fpage>69</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.4161/mabs.4.1.18713</pub-id><pub-id pub-id-type="pmid">22327431</pub-id><pub-id pub-id-type="pmcid">PMC3338942</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutherland</surname><given-names>AP</given-names></name><name name-style="western"><surname>Van Belle</surname><given-names>T</given-names></name><name name-style="western"><surname>Wurster</surname><given-names>AL</given-names></name><name name-style="western"><surname>Suto</surname><given-names>A</given-names></name><name name-style="western"><surname>Michaud</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Interleukin-21 is required for the development of type 1 diabetes in NOD mice</article-title>. <source>Diabetes</source> (<year>2009</year>) <volume>58</volume>(<issue>5</issue>):<fpage>1144</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.2337/db08-0882</pub-id><pub-id pub-id-type="pmid">19208913</pub-id><pub-id pub-id-type="pmcid">PMC2671036</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuriya</surname><given-names>G</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>T</given-names></name><name name-style="western"><surname>Akazawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Double deficiency in IL-17 and IFN-gamma signalling significantly suppresses the development of diabetes in the NOD mouse</article-title>. <source>Diabetologia</source> (<year>2013</year>) <volume>56</volume>(<issue>8</issue>):<fpage>1773</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1007/s00125-013-2935-8</pub-id><pub-id pub-id-type="pmid">23699989</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spolski</surname><given-names>R</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>. <article-title>IL-21 signaling is critical for the development of type I diabetes in the NOD mouse</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2008</year>) <volume>105</volume>(<issue>37</issue>):<fpage>14028</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0804358105</pub-id><pub-id pub-id-type="pmid">18779574</pub-id><pub-id pub-id-type="pmcid">PMC2544573</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenefeck</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kapadi</surname><given-names>T</given-names></name><name name-style="western"><surname>Wardzinski</surname><given-names>L</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>K</given-names></name><name name-style="western"><surname>Clough</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Follicular helper T cell signature in type 1 diabetes</article-title>. <source>J Clin Invest</source> (<year>2015</year>) <volume>125</volume>(<issue>1</issue>):<fpage>292</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="doi">10.1172/JCI76238</pub-id><pub-id pub-id-type="pmid">25485678</pub-id><pub-id pub-id-type="pmcid">PMC4382272</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>HM</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Vogelzang</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Webster</surname><given-names>KE</given-names></name><name name-style="western"><surname>Sprent</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models</article-title>. <source>Diabetes</source> (<year>2011</year>) <volume>60</volume>(<issue>3</issue>):<fpage>867</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.2337/db10-1157</pub-id><pub-id pub-id-type="pmid">21357471</pub-id><pub-id pub-id-type="pmcid">PMC3046847</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>MN</given-names></name><name name-style="western"><surname>von Herrath</surname><given-names>MG</given-names></name><name name-style="western"><surname>Vela</surname><given-names>JL</given-names></name></person-group><article-title>Antigen-specific regulatory T cells and low dose of IL-2 in treatment of type 1 diabetes</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>6</volume>:<fpage>651</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00651</pub-id><pub-id pub-id-type="pmid">26793191</pub-id><pub-id pub-id-type="pmcid">PMC4707297</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>CJ</given-names></name></person-group><article-title>IL-2 therapy in type 1 diabetes: &#8220;trials&#8221; and tribulations</article-title>. <source>Clin Immunol</source> (<year>2013</year>) <volume>149</volume>(<issue>3</issue>):<fpage>324</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2013.02.005</pub-id><pub-id pub-id-type="pmid">23499139</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwyer</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ward</surname><given-names>NC</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></name><name name-style="western"><surname>Malek</surname><given-names>TR</given-names></name></person-group>. <article-title>Promoting immune regulation in type 1 diabetes using low-dose interleukin-2</article-title>. <source>Curr Diab Rep</source> (<year>2016</year>) <volume>16</volume>(<issue>6</issue>):<fpage>46</fpage>.<pub-id pub-id-type="doi">10.1007/s11892-016-0739-1</pub-id><pub-id pub-id-type="pmid">27076179</pub-id><pub-id pub-id-type="pmcid">PMC5907489</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>AL</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>A</given-names></name><name name-style="western"><surname>Malek</surname><given-names>TR</given-names></name></person-group>. <article-title>The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation</article-title>. <source>Immunol Res</source> (<year>2013</year>) <volume>57</volume>(<issue>1&#8211;3</issue>):<fpage>197</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="doi">10.1007/s12026-013-8452-5</pub-id><pub-id pub-id-type="pmid">24214027</pub-id><pub-id pub-id-type="pmcid">PMC3990437</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyman</surname><given-names>O</given-names></name><name name-style="western"><surname>Sprent</surname><given-names>J</given-names></name></person-group>. <article-title>The role of interleukin-2 during homeostasis and activation of the immune system</article-title>. <source>Nat Rev Immunol</source> (<year>2012</year>) <volume>12</volume>(<issue>3</issue>):<fpage>180</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1038/nri3156</pub-id><pub-id pub-id-type="pmid">22343569</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setoguchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Hori</surname><given-names>S</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group>. <article-title>Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>(<issue>5</issue>):<fpage>723</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20041982</pub-id><pub-id pub-id-type="pmid">15753206</pub-id><pub-id pub-id-type="pmcid">PMC2212841</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Altman</surname><given-names>NH</given-names></name><name name-style="western"><surname>Malek</surname><given-names>TR</given-names></name></person-group>. <article-title>A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells</article-title>. <source>Immunity</source> (<year>2009</year>) <volume>30</volume>(<issue>2</issue>):<fpage>204</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2008.11.014</pub-id><pub-id pub-id-type="pmid">19185518</pub-id><pub-id pub-id-type="pmcid">PMC2962446</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barron</surname><given-names>L</given-names></name><name name-style="western"><surname>Dooms</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>KK</given-names></name><name name-style="western"><surname>Kuswanto</surname><given-names>W</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>J</given-names></name><name name-style="western"><surname>O&#8217;Gorman</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>(<issue>11</issue>):<fpage>6426</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0903940</pub-id><pub-id pub-id-type="pmid">21037099</pub-id><pub-id pub-id-type="pmcid">PMC3059533</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koreth</surname><given-names>J</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HT</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bindra</surname><given-names>B</given-names></name><name name-style="western"><surname>Alyea</surname><given-names>EP</given-names><suffix>III</suffix></name><etal/></person-group><article-title>Interleukin-2 and regulatory T cells in graft-versus-host disease</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>365</volume>(<issue>22</issue>):<fpage>2055</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1108188</pub-id><pub-id pub-id-type="pmid">22129252</pub-id><pub-id pub-id-type="pmcid">PMC3727432</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saadoun</surname><given-names>D</given-names></name><name name-style="western"><surname>Rosenzwajg</surname><given-names>M</given-names></name><name name-style="western"><surname>Joly</surname><given-names>F</given-names></name><name name-style="western"><surname>Six</surname><given-names>A</given-names></name><name name-style="western"><surname>Carrat</surname><given-names>F</given-names></name><name name-style="western"><surname>Thibault</surname><given-names>V</given-names></name><etal/></person-group><article-title>Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>365</volume>(<issue>22</issue>):<fpage>2067</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1105143</pub-id><pub-id pub-id-type="pmid">22129253</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grinberg-Bleyer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baeyens</surname><given-names>A</given-names></name><name name-style="western"><surname>You</surname><given-names>S</given-names></name><name name-style="western"><surname>Elhage</surname><given-names>R</given-names></name><name name-style="western"><surname>Fourcade</surname><given-names>G</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>S</given-names></name><etal/></person-group><article-title>IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>(<issue>9</issue>):<fpage>1871</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20100209</pub-id><pub-id pub-id-type="pmid">20679400</pub-id><pub-id pub-id-type="pmcid">PMC2931175</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabinovitch</surname><given-names>A</given-names></name><name name-style="western"><surname>Suarez-Pinzon</surname><given-names>WL</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rajotte</surname><given-names>RV</given-names></name><name name-style="western"><surname>Power</surname><given-names>R</given-names></name></person-group>. <article-title>Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice</article-title>. <source>Diabetes</source> (<year>2002</year>) <volume>51</volume>(<issue>3</issue>):<fpage>638</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.51.3.638</pub-id><pub-id pub-id-type="pmid">11872661</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rieck</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanda</surname><given-names>S</given-names></name><name name-style="western"><surname>Bollyky</surname><given-names>JB</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>PL</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function</article-title>. <source>Diabetes</source> (<year>2012</year>) <volume>61</volume>(<issue>9</issue>):<fpage>2340</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.2337/db12-0049</pub-id><pub-id pub-id-type="pmid">22721971</pub-id><pub-id pub-id-type="pmcid">PMC3425404</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenzwajg</surname><given-names>M</given-names></name><name name-style="western"><surname>Churlaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Mallone</surname><given-names>R</given-names></name><name name-style="western"><surname>Six</surname><given-names>A</given-names></name><name name-style="western"><surname>Derian</surname><given-names>N</given-names></name><name name-style="western"><surname>Chaara</surname><given-names>W</given-names></name><etal/></person-group><article-title>Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients</article-title>. <source>J Autoimmun</source> (<year>2015</year>) <volume>58</volume>:<fpage>48</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2015.01.001</pub-id><pub-id pub-id-type="pmid">25634360</pub-id><pub-id pub-id-type="pmcid">PMC8153751</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartemann</surname><given-names>A</given-names></name><name name-style="western"><surname>Bensimon</surname><given-names>G</given-names></name><name name-style="western"><surname>Payan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Jacqueminet</surname><given-names>S</given-names></name><name name-style="western"><surname>Bourron</surname><given-names>O</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>N</given-names></name><etal/></person-group><article-title>Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Diabetes Endocrinol</source> (<year>2013</year>) <volume>1</volume>(<issue>4</issue>):<fpage>295</fpage>&#8211;<lpage>305</lpage>.<pub-id pub-id-type="doi">10.1016/S2213-8587(13)70113-X</pub-id><pub-id pub-id-type="pmid">24622415</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sockolosky</surname><given-names>JT</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>E</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>G</given-names></name><name name-style="western"><surname>Picton</surname><given-names>L</given-names></name><name name-style="western"><surname>Su</surname><given-names>LL</given-names></name><name name-style="western"><surname>Le</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes</article-title>. <source>Science</source> (<year>2018</year>) <volume>359</volume>(<issue>6379</issue>):<fpage>1037</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1126/science.aar3246</pub-id><pub-id pub-id-type="pmid">29496879</pub-id><pub-id pub-id-type="pmcid">PMC5947856</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyman</surname><given-names>O</given-names></name><name name-style="western"><surname>Kovar</surname><given-names>M</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>MP</given-names></name><name name-style="western"><surname>Surh</surname><given-names>CD</given-names></name><name name-style="western"><surname>Sprent</surname><given-names>J</given-names></name></person-group>. <article-title>Selective stimulation of T cell subsets with antibody-cytokine immune complexes</article-title>. <source>Science</source> (<year>2006</year>) <volume>311</volume>(<issue>5769</issue>):<fpage>1924</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1126/science.1122927</pub-id><pub-id pub-id-type="pmid">16484453</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>KE</given-names></name><name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>RE</given-names></name><name name-style="western"><surname>Mrkvan</surname><given-names>T</given-names></name><name name-style="western"><surname>Boyman</surname><given-names>O</given-names></name><name name-style="western"><surname>Surh</surname><given-names>CD</given-names></name><etal/></person-group><article-title>In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression</article-title>. <source>J Exp Med</source> (<year>2009</year>) <volume>206</volume>(<issue>4</issue>):<fpage>751</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20082824</pub-id><pub-id pub-id-type="pmid">19332874</pub-id><pub-id pub-id-type="pmcid">PMC2715127</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manirarora</surname><given-names>JN</given-names></name><name name-style="western"><surname>Wei</surname><given-names>CH</given-names></name></person-group>. <article-title>Combination therapy using IL-2/IL-2 monoclonal antibody complexes, rapamycin, and islet autoantigen peptides increases regulatory T cell frequency and protects against spontaneous and induced type 1 diabetes in nonobese diabetic mice</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>(<issue>11</issue>):<fpage>5203</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1402540</pub-id><pub-id pub-id-type="pmid">26482409</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spangler</surname><given-names>JB</given-names></name><name name-style="western"><surname>Tomala</surname><given-names>J</given-names></name><name name-style="western"><surname>Luca</surname><given-names>VC</given-names></name><name name-style="western"><surname>Jude</surname><given-names>KM</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Ring</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>42</volume>(<issue>5</issue>):<fpage>815</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.04.015</pub-id><pub-id pub-id-type="pmid">25992858</pub-id><pub-id pub-id-type="pmcid">PMC4439582</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group>. <article-title>Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes</article-title>. <source>Hum Vaccin</source> (<year>2011</year>) <volume>7</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.4161/hv.7.1.12848</pub-id><pub-id pub-id-type="pmid">21157183</pub-id><pub-id pub-id-type="pmcid">PMC3062240</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grieger</surname><given-names>JC</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></name></person-group>. <article-title>Adeno-associated virus vectorology, manufacturing, and clinical applications</article-title>. <source>Methods Enzymol</source> (<year>2012</year>) <volume>507</volume>:<fpage>229</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/B978-0-12-386509-0.00012-0</pub-id><pub-id pub-id-type="pmid">22365777</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manzoor</surname><given-names>F</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group><article-title>beta-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice</article-title>. <source>Eur J Immunol</source> (<year>2017</year>) <volume>47</volume>(<issue>1</issue>):<fpage>144</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201646493</pub-id><pub-id pub-id-type="pmid">27859048</pub-id><pub-id pub-id-type="pmcid">PMC5233468</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name></person-group><article-title>Protective role of adenovirus vector-mediated interleukin-10 gene therapy on endogenous islet beta-cells in recent-onset type 1 diabetes in NOD mice</article-title>. <source>Exp Ther Med</source> (<year>2016</year>) <volume>11</volume>(<issue>5</issue>):<fpage>1625</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.3892/etm.2016.3169</pub-id><pub-id pub-id-type="pmid">27168782</pub-id><pub-id pub-id-type="pmcid">PMC4840566</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallol</surname><given-names>C</given-names></name><name name-style="western"><surname>Casana</surname><given-names>E</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>V</given-names></name><name name-style="western"><surname>Casellas</surname><given-names>A</given-names></name><name name-style="western"><surname>Haurigot</surname><given-names>V</given-names></name><name name-style="western"><surname>Jambrina</surname><given-names>C</given-names></name><etal/></person-group><article-title>AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice</article-title>. <source>Mol Metab</source> (<year>2017</year>) <volume>6</volume>(<issue>7</issue>):<fpage>664</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmet.2017.05.007</pub-id><pub-id pub-id-type="pmid">28702323</pub-id><pub-id pub-id-type="pmcid">PMC5485311</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>Goudy</surname><given-names>K</given-names></name><name name-style="western"><surname>Campbell-Thompson</surname><given-names>M</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>C</given-names></name><name name-style="western"><surname>Scott-Jorgensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice</article-title>. <source>Gene Ther</source> (<year>2004</year>) <volume>11</volume>(<issue>2</issue>):<fpage>181</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/sj.gt.3302156</pub-id><pub-id pub-id-type="pmid">14712302</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Buckner</surname><given-names>JH</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Hellerstein</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Type 1 diabetes immunotherapy using polyclonal regulatory T cells</article-title>. <source>Sci Transl Med</source> (<year>2015</year>) <volume>7</volume>(<issue>315</issue>):<fpage>315ra189</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.aad4134</pub-id><pub-id pub-id-type="pmid">26606968</pub-id><pub-id pub-id-type="pmcid">PMC4729454</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>E</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name></person-group>. <article-title>The therapeutic potential of regulatory T cells for the treatment of autoimmune disease</article-title>. <source>Expert Opin Ther Targets</source> (<year>2015</year>) <volume>19</volume>(<issue>8</issue>):<fpage>1091</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1517/14728222.2015.1037282</pub-id><pub-id pub-id-type="pmid">25881491</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name></person-group>. <article-title>Regulatory T cell therapy for type 1 diabetes: may the force be with you</article-title>. <source>J Autoimmun</source> (<year>2016</year>) <volume>71</volume>:<fpage>78</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2016.03.011</pub-id><pub-id pub-id-type="pmid">27133597</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bi</surname><given-names>M</given-names></name><name name-style="western"><surname>Finger</surname><given-names>EB</given-names></name><name name-style="western"><surname>Szot</surname><given-names>G</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><etal/></person-group><article-title>In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>(<issue>11</issue>):<fpage>1455</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20040139</pub-id><pub-id pub-id-type="pmid">15184499</pub-id><pub-id pub-id-type="pmcid">PMC2211775</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putnam</surname><given-names>AL</given-names></name><name name-style="western"><surname>Brusko</surname><given-names>TM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MR</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Szot</surname><given-names>GL</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expansion of human regulatory T-cells from patients with type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2009</year>) <volume>58</volume>(<issue>3</issue>):<fpage>652</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.2337/db08-1168</pub-id><pub-id pub-id-type="pmid">19074986</pub-id><pub-id pub-id-type="pmcid">PMC2646064</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyara</surname><given-names>M</given-names></name><name name-style="western"><surname>Chader</surname><given-names>D</given-names></name><name name-style="western"><surname>Burlion</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>J</given-names></name><name name-style="western"><surname>Sterlin</surname><given-names>D</given-names></name><name name-style="western"><surname>Norol</surname><given-names>F</given-names></name><etal/></person-group><article-title>Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>(<issue>62</issue>):<fpage>104733</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.18632/oncotarget.10914</pub-id><pub-id pub-id-type="pmid">29285209</pub-id><pub-id pub-id-type="pmcid">PMC5739596</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group>. <article-title>Role of intestinal microbiota and metabolites on gut homeostasis and human diseases</article-title>. <source>BMC Immunol</source> (<year>2017</year>) <volume>18</volume>(<issue>1</issue>):<fpage>2</fpage>.<pub-id pub-id-type="doi">10.1186/s12865-016-0187-3</pub-id><pub-id pub-id-type="pmid">28061847</pub-id><pub-id pub-id-type="pmcid">PMC5219689</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkanani</surname><given-names>AK</given-names></name><name name-style="western"><surname>Hara</surname><given-names>N</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Ir</surname><given-names>D</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes</article-title>. <source>Diabetes</source> (<year>2015</year>) <volume>64</volume>(<issue>10</issue>):<fpage>3510</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.2337/db14-1847</pub-id><pub-id pub-id-type="pmid">26068542</pub-id><pub-id pub-id-type="pmcid">PMC4587635</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunne</surname><given-names>JL</given-names></name><name name-style="western"><surname>Triplett</surname><given-names>EW</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>D</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R</given-names></name><name name-style="western"><surname>Insel</surname><given-names>R</given-names></name><name name-style="western"><surname>Danska</surname><given-names>J</given-names></name><etal/></person-group><article-title>The intestinal microbiome in type 1 diabetes</article-title>. <source>Clin Exp Immunol</source> (<year>2014</year>) <volume>177</volume>(<issue>1</issue>):<fpage>30</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1111/cei.12321</pub-id><pub-id pub-id-type="pmid">24628412</pub-id><pub-id pub-id-type="pmcid">PMC4089152</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><article-title>Pathogen recognition and innate immunity</article-title>. <source>Cell</source> (<year>2006</year>) <volume>124</volume>(<issue>4</issue>):<fpage>783</fpage>&#8211;<lpage>801</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troutman</surname><given-names>TD</given-names></name><name name-style="western"><surname>Bazan</surname><given-names>JF</given-names></name><name name-style="western"><surname>Pasare</surname><given-names>C</given-names></name></person-group>. <article-title>Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K</article-title>. <source>Cell Cycle</source> (<year>2012</year>) <volume>11</volume>(<issue>19</issue>):<fpage>3559</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.4161/cc.21572</pub-id><pub-id pub-id-type="pmid">22895011</pub-id><pub-id pub-id-type="pmcid">PMC3478307</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markle</surname><given-names>JG</given-names></name><name name-style="western"><surname>Frank</surname><given-names>DN</given-names></name><name name-style="western"><surname>Mortin-Toth</surname><given-names>S</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Feazel</surname><given-names>LM</given-names></name><name name-style="western"><surname>Rolle-Kampczyk</surname><given-names>U</given-names></name><etal/></person-group><article-title>Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>(<issue>6123</issue>):<fpage>1084</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.1233521</pub-id><pub-id pub-id-type="pmid">23328391</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murri</surname><given-names>M</given-names></name><name name-style="western"><surname>Leiva</surname><given-names>I</given-names></name><name name-style="western"><surname>Gomez-Zumaquero</surname><given-names>JM</given-names></name><name name-style="western"><surname>Tinahones</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>F</given-names></name><name name-style="western"><surname>Soriguer</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study</article-title>. <source>BMC Med</source> (<year>2013</year>) <volume>11</volume>:<fpage>46</fpage>.<pub-id pub-id-type="doi">10.1186/1741-7015-11-46</pub-id><pub-id pub-id-type="pmid">23433344</pub-id><pub-id pub-id-type="pmcid">PMC3621820</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>N</given-names></name><name name-style="western"><surname>Wong</surname><given-names>FS</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L</given-names></name></person-group>. <article-title>The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity</article-title>. <source>Rev Endocr Metab Disord</source> (<year>2015</year>) <volume>16</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1007/s11154-015-9309-0</pub-id><pub-id pub-id-type="pmid">25619480</pub-id><pub-id pub-id-type="pmcid">PMC4348024</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Goffau</surname><given-names>MC</given-names></name><name name-style="western"><surname>Luopajarvi</surname><given-names>K</given-names></name><name name-style="western"><surname>Knip</surname><given-names>M</given-names></name><name name-style="western"><surname>Ilonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruohtula</surname><given-names>T</given-names></name><name name-style="western"><surname>Harkonen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Fecal microbiota composition differs between children with beta-cell autoimmunity and those without</article-title>. <source>Diabetes</source> (<year>2013</year>) <volume>62</volume>(<issue>4</issue>):<fpage>1238</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.2337/db12-0526</pub-id><pub-id pub-id-type="pmid">23274889</pub-id><pub-id pub-id-type="pmcid">PMC3609581</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kostic</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>D</given-names></name><name name-style="western"><surname>Siljander</surname><given-names>H</given-names></name><name name-style="western"><surname>Vatanen</surname><given-names>T</given-names></name><name name-style="western"><surname>Hyotylainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Hamalainen</surname><given-names>AM</given-names></name><etal/></person-group><article-title>The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes</article-title>. <source>Cell Host Microbe</source> (<year>2015</year>) <volume>17</volume>(<issue>2</issue>):<fpage>260</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2015.01.001</pub-id><pub-id pub-id-type="pmid">25662751</pub-id><pub-id pub-id-type="pmcid">PMC4689191</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endesfelder</surname><given-names>D</given-names></name><name name-style="western"><surname>Zu Castell</surname><given-names>W</given-names></name><name name-style="western"><surname>Ardissone</surname><given-names>A</given-names></name><name name-style="western"><surname>Davis-Richardson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Achenbach</surname><given-names>P</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Compromised gut microbiota networks in children with anti-islet cell autoimmunity</article-title>. <source>Diabetes</source> (<year>2014</year>) <volume>63</volume>(<issue>6</issue>):<fpage>2006</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.2337/db13-1676</pub-id><pub-id pub-id-type="pmid">24608442</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giongo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gano</surname><given-names>KA</given-names></name><name name-style="western"><surname>Crabb</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>N</given-names></name><name name-style="western"><surname>Novelo</surname><given-names>LL</given-names></name><name name-style="western"><surname>Casella</surname><given-names>G</given-names></name><etal/></person-group><article-title>Toward defining the autoimmune microbiome for type 1 diabetes</article-title>. <source>ISME J</source> (<year>2011</year>) <volume>5</volume>(<issue>1</issue>):<fpage>82</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/ismej.2010.92</pub-id><pub-id pub-id-type="pmid">20613793</pub-id><pub-id pub-id-type="pmcid">PMC3105672</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>E</given-names></name><name name-style="western"><surname>Richards</surname><given-names>JL</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>KH</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>D</given-names></name><name name-style="western"><surname>Yap</surname><given-names>YA</given-names></name><name name-style="western"><surname>Knight</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>(<issue>5</issue>):<fpage>552</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3713</pub-id><pub-id pub-id-type="pmid">28346408</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Santamaria</surname><given-names>P</given-names></name></person-group>. <article-title>Antigen-specific therapeutic approaches in Type 1 diabetes</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2012</year>) <volume>2</volume>(<issue>2</issue>):<fpage>a007773</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a007773</pub-id><pub-id pub-id-type="pmid">22355799</pub-id><pub-id pub-id-type="pmcid">PMC3281592</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>SD</given-names></name><name name-style="western"><surname>Turley</surname><given-names>DM</given-names></name><name name-style="western"><surname>Podojil</surname><given-names>JR</given-names></name></person-group>. <article-title>Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>9</issue>):<fpage>665</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1038/nri2153</pub-id><pub-id pub-id-type="pmid">17690713</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>EL</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name></person-group>. <article-title>Peptide immunotherapy for type 1 diabetes-clinical advances</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<fpage>392</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2018.00392</pub-id><pub-id pub-id-type="pmid">29541078</pub-id><pub-id pub-id-type="pmcid">PMC5836708</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzilli</surname><given-names>P</given-names></name><name name-style="western"><surname>Gisella Cavallo</surname><given-names>M</given-names></name></person-group>. <article-title>Oral insulin and the induction of tolerance in man: reality or fantasy?</article-title><source>Diabetes Metab Res Rev</source> (<year>2000</year>) <volume>16</volume>(<issue>5</issue>):<fpage>306</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1520-7560(200009/10)16:5&amp;#x0003c;306::AID-DMRR150&amp;#x0003e;3.0.CO;2-J</pub-id><pub-id pub-id-type="pmid">11025554</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skyler</surname><given-names>JS</given-names></name></person-group><article-title>Type 1 diabetes TrialNet Study G. Update on worldwide efforts to prevent type 1 diabetes</article-title>. <source>Ann N Y Acad Sci</source> (<year>2008</year>) <volume>1150</volume>:<fpage>190</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1196/annals.1447.055</pub-id><pub-id pub-id-type="pmid">19120293</pub-id><pub-id pub-id-type="pmcid">PMC2928677</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skyler</surname><given-names>JS</given-names></name><name name-style="western"><surname>Krischer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wolfsdorf</surname><given-names>J</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>C</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>JP</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial &#8211; type 1</article-title>. <source>Diabetes Care</source> (<year>2005</year>) <volume>28</volume>(<issue>5</issue>):<fpage>1068</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.2337/diacare.28.5.1068</pub-id><pub-id pub-id-type="pmid">15855569</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzilli</surname><given-names>P</given-names></name><name name-style="western"><surname>Pitocco</surname><given-names>D</given-names></name><name name-style="western"><surname>Visalli</surname><given-names>N</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>MG</given-names></name><name name-style="western"><surname>Buzzetti</surname><given-names>R</given-names></name><name name-style="western"><surname>Crino</surname><given-names>A</given-names></name><etal/></person-group><article-title>No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group</article-title>. <source>Diabetologia</source> (<year>2000</year>) <volume>43</volume>(<issue>8</issue>):<fpage>1000</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1007/s001250051482</pub-id><pub-id pub-id-type="pmid">10990077</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaillous</surname><given-names>L</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>H</given-names></name><name name-style="western"><surname>Thivolet</surname><given-names>C</given-names></name><name name-style="western"><surname>Boitard</surname><given-names>C</given-names></name><name name-style="western"><surname>Lahlou</surname><given-names>N</given-names></name><name name-style="western"><surname>Atlan-Gepner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group</article-title>. <source>Lancet</source> (<year>2000</year>) <volume>356</volume>(<issue>9229</issue>):<fpage>545</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(00)02579-4</pub-id><pub-id pub-id-type="pmid">10950231</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wherrett</surname><given-names>DK</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>DiMeglio</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial</article-title>. <source>Lancet</source> (<year>2011</year>) <volume>378</volume>(<issue>9788</issue>):<fpage>319</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60895-7</pub-id><pub-id pub-id-type="pmid">21714999</pub-id><pub-id pub-id-type="pmcid">PMC3580128</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludvigsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Krisky</surname><given-names>D</given-names></name><name name-style="western"><surname>Casas</surname><given-names>R</given-names></name><name name-style="western"><surname>Battelino</surname><given-names>T</given-names></name><name name-style="western"><surname>Castano</surname><given-names>L</given-names></name><name name-style="western"><surname>Greening</surname><given-names>J</given-names></name><etal/></person-group><article-title>GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>5</issue>):<fpage>433</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1107096</pub-id><pub-id pub-id-type="pmid">22296077</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awate</surname><given-names>S</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>LA</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></name></person-group>. <article-title>Mechanisms of action of adjuvants</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>114</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2013.00114</pub-id><pub-id pub-id-type="pmid">23720661</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Axelsson</surname><given-names>S</given-names></name><name name-style="western"><surname>Hjorth</surname><given-names>M</given-names></name><name name-style="western"><surname>Akerman</surname><given-names>L</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Casas</surname><given-names>R</given-names></name></person-group>. <article-title>Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65)</article-title>. <source>Diabetes Metab Res Rev</source> (<year>2010</year>) <volume>26</volume>(<issue>7</issue>):<fpage>559</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1002/dmrr.1126</pub-id><pub-id pub-id-type="pmid">20830731</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alleva</surname><given-names>DG</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Pahuja</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide</article-title>. <source>Diabetes</source> (<year>2002</year>) <volume>51</volume>(<issue>7</issue>):<fpage>2126</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.2337/diabetes.51.7.2126</pub-id><pub-id pub-id-type="pmid">12086942</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>M</given-names></name><name name-style="western"><surname>Philotheou</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonnici</surname><given-names>F</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>AG</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>R</given-names></name><name name-style="western"><surname>Group</surname><given-names>NBIS</given-names></name></person-group>. <article-title>No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes</article-title>. <source>Diabetes Care</source> (<year>2009</year>) <volume>32</volume>(<issue>11</issue>):<fpage>2036</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.2337/dc09-0449</pub-id><pub-id pub-id-type="pmid">19690081</pub-id><pub-id pub-id-type="pmcid">PMC2768201</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thrower</surname><given-names>SL</given-names></name><name name-style="western"><surname>James</surname><given-names>L</given-names></name><name name-style="western"><surname>Hall</surname><given-names>W</given-names></name><name name-style="western"><surname>Green</surname><given-names>KM</given-names></name><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study</article-title>. <source>Clin Exp Immunol</source> (<year>2009</year>) <volume>155</volume>(<issue>2</issue>):<fpage>156</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03814.x</pub-id><pub-id pub-id-type="pmid">19040615</pub-id><pub-id pub-id-type="pmcid">PMC2675245</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alhadj Ali</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Tatovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Shariff</surname><given-names>H</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>VB</given-names></name><etal/></person-group><article-title>Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes</article-title>. <source>Sci Transl Med</source> (<year>2017</year>) <volume>9</volume>(<issue>402</issue>):<fpage>eaaf7779</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf7779</pub-id><pub-id pub-id-type="pmid">28794283</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnelly</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wahren</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MA</given-names></name></person-group>. <article-title>DNA vaccines: progress and challenges</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>175</volume>(<issue>2</issue>):<fpage>633</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.175.2.633</pub-id><pub-id pub-id-type="pmid">16002657</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulhaqq</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group>. <article-title>DNA vaccines: developing new strategies to enhance immune responses</article-title>. <source>Immunol Res</source> (<year>2008</year>) <volume>42</volume>(<issue>1&#8211;3</issue>):<fpage>219</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1007/s12026-008-8076-3</pub-id><pub-id pub-id-type="pmid">19066740</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goudy</surname><given-names>KS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group>. <article-title>Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice</article-title>. <source>Clin Immunol</source> (<year>2008</year>) <volume>129</volume>(<issue>1</issue>):<fpage>49</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2008.06.001</pub-id><pub-id pub-id-type="pmid">18675592</pub-id><pub-id pub-id-type="pmcid">PMC2593033</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Bui</surname><given-names>T</given-names></name><name name-style="western"><surname>Arthos</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>(<issue>3</issue>):<fpage>2122</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.166.3.2122</pub-id><pub-id pub-id-type="pmid">11160264</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seifarth</surname><given-names>C</given-names></name><name name-style="western"><surname>Pop</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CP</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group>. <article-title>More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>171</volume>(<issue>1</issue>):<fpage>469</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.171.1.469</pub-id><pub-id pub-id-type="pmid">12817032</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Tisch</surname><given-names>R</given-names></name></person-group>. <article-title>Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>167</volume>(<issue>1</issue>):<fpage>586</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.167.1.586</pub-id><pub-id pub-id-type="pmid">11418698</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roep</surname><given-names>BO</given-names></name><name name-style="western"><surname>Solvason</surname><given-names>N</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>PA</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>JRF</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LC</given-names></name><name name-style="western"><surname>Eisenbarth</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes</article-title>. <source>Sci Transl Med</source> (<year>2013</year>) <volume>5</volume>(<issue>191</issue>):<fpage>191ra82</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3006103</pub-id><pub-id pub-id-type="pmcid">PMC4516024</pub-id><pub-id pub-id-type="pmid">23803704</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keselowsky</surname><given-names>BG</given-names></name><name name-style="western"><surname>Xia</surname><given-names>CQ</given-names></name><name name-style="western"><surname>Clare-Salzler</surname><given-names>M</given-names></name></person-group><article-title>Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes</article-title>. <source>Hum Vaccin</source> (<year>2011</year>) <volume>7</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.4161/hv.7.1.12916</pub-id><pub-id pub-id-type="pmid">21157186</pub-id><pub-id pub-id-type="pmcid">PMC3679212</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JS</given-names></name><name name-style="western"><surname>Allen</surname><given-names>RP</given-names></name></person-group>. <article-title>An introduction to biomaterial-based strategies for curbing autoimmunity</article-title>. <source>Exp Biol Med (Maywood)</source> (<year>2016</year>) <volume>241</volume>(<issue>10</issue>):<fpage>1107</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1177/1535370216650294</pub-id><pub-id pub-id-type="pmid">27229905</pub-id><pub-id pub-id-type="pmcid">PMC4950372</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachelder</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pino</surname><given-names>EN</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>KM</given-names></name></person-group>. <article-title>Acetalated dextran: a tunable and acid-labile biopolymer with facile synthesis and a range of applications</article-title>. <source>Chem Rev</source> (<year>2017</year>) <volume>117</volume>(<issue>3</issue>):<fpage>1915</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00532</pub-id><pub-id pub-id-type="pmid">28032507</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><name name-style="western"><surname>Collier</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>MD</given-names></name><name name-style="western"><surname>Collins</surname><given-names>GC</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>CC</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>EQ</given-names></name><etal/></person-group><article-title>Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight</article-title>. <source>Int J Pharm</source> (<year>2016</year>) <volume>512</volume>(<issue>1</issue>):<fpage>147</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.08.031</pub-id><pub-id pub-id-type="pmid">27543351</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wattendorf</surname><given-names>U</given-names></name><name name-style="western"><surname>Coullerez</surname><given-names>G</given-names></name><name name-style="western"><surname>Voros</surname><given-names>J</given-names></name><name name-style="western"><surname>Textor</surname><given-names>M</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>HP</given-names></name></person-group>. <article-title>Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells</article-title>. <source>Langmuir</source> (<year>2008</year>) <volume>24</volume>(<issue>20</issue>):<fpage>11790</fpage>&#8211;<lpage>802</lpage>.<pub-id pub-id-type="doi">10.1021/la801085d</pub-id><pub-id pub-id-type="pmid">18785716</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>YJ</given-names></name><name name-style="western"><surname>James</surname><given-names>E</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>N</given-names></name><name name-style="western"><surname>Frechet</surname><given-names>JM</given-names></name></person-group>. <article-title>In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>(<issue>51</issue>):<fpage>18264</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0509541102</pub-id><pub-id pub-id-type="pmid">16344458</pub-id><pub-id pub-id-type="pmcid">PMC1317987</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Fokkink</surname><given-names>R</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>B</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>MC</given-names></name><name name-style="western"><surname>Albericio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro</article-title>. <source>J Control Release</source> (<year>2010</year>) <volume>144</volume>(<issue>2</issue>):<fpage>118</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.jconrel.2010.02.013</pub-id><pub-id pub-id-type="pmid">20156497</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machen</surname><given-names>J</given-names></name><name name-style="western"><surname>Harnaha</surname><given-names>J</given-names></name><name name-style="western"><surname>Lakomy</surname><given-names>R</given-names></name><name name-style="western"><surname>Styche</surname><given-names>A</given-names></name><name name-style="western"><surname>Trucco</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannoukakis</surname><given-names>N</given-names></name></person-group>. <article-title>Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>(<issue>7</issue>):<fpage>4331</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.173.7.4331</pub-id><pub-id pub-id-type="pmid">15383562</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>B</given-names></name><name name-style="western"><surname>Nylander</surname><given-names>K</given-names></name><name name-style="western"><surname>Harnaha</surname><given-names>J</given-names></name><name name-style="western"><surname>Machen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lakomy</surname><given-names>R</given-names></name><name name-style="western"><surname>Styche</surname><given-names>A</given-names></name><etal/></person-group><article-title>A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes</article-title>. <source>Diabetes</source> (<year>2008</year>) <volume>57</volume>(<issue>6</issue>):<fpage>1544</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.2337/db07-0507</pub-id><pub-id pub-id-type="pmid">18316361</pub-id><pub-id pub-id-type="pmcid">PMC2713034</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engman</surname><given-names>C</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>WS</given-names></name><name name-style="western"><surname>Bottino</surname><given-names>R</given-names></name><name name-style="western"><surname>Trucco</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannoukakis</surname><given-names>N</given-names></name></person-group>. <article-title>Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation</article-title>. <source>Clin Immunol</source> (<year>2015</year>) <volume>160</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2015.03.004</pub-id><pub-id pub-id-type="pmid">25773782</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeste</surname><given-names>A</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mascanfroni</surname><given-names>ID</given-names></name><name name-style="western"><surname>Nadeau</surname><given-names>M</given-names></name><name name-style="western"><surname>Kenison</surname><given-names>JE</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2</article-title>. <source>Sci Signal</source> (<year>2016</year>) <volume>9</volume>(<issue>433</issue>):<fpage>ra61</fpage>.<pub-id pub-id-type="doi">10.1126/scisignal.aad0612</pub-id><pub-id pub-id-type="pmid">27330188</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shameli</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamanouchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Serra</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reversal of autoimmunity by boosting memory-like autoregulatory T cells</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>32</volume>(<issue>4</issue>):<fpage>568</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2010.03.015</pub-id><pub-id pub-id-type="pmid">20381385</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J</given-names></name><name name-style="western"><surname>Ambalavanan</surname><given-names>P</given-names></name><name name-style="western"><surname>Yamanouchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Singha</surname><given-names>S</given-names></name><name name-style="western"><surname>Fandos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Expanding antigen-specific regulatory networks to treat autoimmunity</article-title>. <source>Nature</source> (<year>2016</year>) <volume>530</volume>(<issue>7591</issue>):<fpage>434</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1038/nature16962</pub-id><pub-id pub-id-type="pmid">26886799</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trahtemberg</surname><given-names>U</given-names></name><name name-style="western"><surname>Mevorach</surname><given-names>D</given-names></name></person-group>. <article-title>Apoptotic cells induced signaling for immune homeostasis in macrophages and dendritic cells</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<fpage>1356</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01356</pub-id><pub-id pub-id-type="pmid">29118755</pub-id><pub-id pub-id-type="pmcid">PMC5661053</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderlugt</surname><given-names>CL</given-names></name><name name-style="western"><surname>Neville</surname><given-names>KL</given-names></name><name name-style="western"><surname>Nikcevich</surname><given-names>KM</given-names></name><name name-style="western"><surname>Eagar</surname><given-names>TN</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>SD</given-names></name></person-group>. <article-title>Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>164</volume>(<issue>2</issue>):<fpage>670</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.164.2.670</pub-id><pub-id pub-id-type="pmid">10623809</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutterotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Yousef</surname><given-names>S</given-names></name><name name-style="western"><surname>Sputtek</surname><given-names>A</given-names></name><name name-style="western"><surname>Sturner</surname><given-names>KH</given-names></name><name name-style="western"><surname>Stellmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Breiden</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis</article-title>. <source>Sci Transl Med</source> (<year>2013</year>) <volume>5</volume>(<issue>188</issue>):<fpage>188ra75</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3006168</pub-id><pub-id pub-id-type="pmid">23740901</pub-id><pub-id pub-id-type="pmcid">PMC3973034</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peschl</surname><given-names>P</given-names></name><name name-style="western"><surname>Reindl</surname><given-names>M</given-names></name><name name-style="western"><surname>Schanda</surname><given-names>K</given-names></name><name name-style="western"><surname>Sospedra</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R</given-names></name><name name-style="western"><surname>Lutterotti</surname><given-names>A</given-names></name></person-group>. <article-title>Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells</article-title>. <source>Mult Scler</source> (<year>2015</year>) <volume>21</volume>(<issue>5</issue>):<fpage>651</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1177/1352458514549405</pub-id><pub-id pub-id-type="pmid">25200502</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>A</given-names></name><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name></person-group>. <article-title>Anti-CD3 mAbs for treatment of type 1 diabetes</article-title>. <source>Diabetes Metab Res Rev</source> (<year>2009</year>) <volume>25</volume>(<issue>4</issue>):<fpage>302</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1002/dmrr.933</pub-id><pub-id pub-id-type="pmid">19319985</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izquierdo</surname><given-names>C</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Presa</surname><given-names>M</given-names></name><name name-style="western"><surname>Malo</surname><given-names>S</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>A</given-names></name><name name-style="western"><surname>Garabatos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>8106</fpage>.<pub-id pub-id-type="doi">10.1038/s41598-018-26161-6</pub-id><pub-id pub-id-type="pmid">29802270</pub-id><pub-id pub-id-type="pmcid">PMC5970271</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>